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ABSTRACT
Pretargeted Radioimmunotherapy Utilizing the Inverse Electron Demand Diels-Alder Reaction
by
Rosemery Membreno

Advisor: Brian M. Zeglis

Radioimmunotherapy capitalizes on the specificity and affinity of antibodies for their
antigens to localize radioactivity at the tumor site. One limitation in using antibodies is their long
circulation time, which can take days to weeks to fully clear from blood circulation. When a
radioisotope is directly conjugated to this immunoglobulin vector, the red marrow and other
healthy organs are receiving a constant radiation dose while it is in blood circulation. This not only
harms healthy organs, but limits the dose of radioactivity that can be administered thus prolonging
treatment. A promising alternative to limit the radiation dose to non-tumor tissue is in vivo
pretargeting based on the inverse electron demand Diels-Alder (IEDDA) reaction between
tetrazine (Tz) and trans-cyclooctene (TCO). This method separates the localization of the antibody
at the tumor site from administration of the radioactivity. It functions in 4 steps: 1) administration
of a TCO-modified antibody, 2) passage of sufficient time for the antibody to accumulate at tumor
site and concurrently clear from blood circulation, 3) injection of a tetrazine-bearing small
molecule radioligand, 4) shorter time interval for the small molecule to clear from the bloodstream.
This method capitalizes on the tumor targeting properties of antibodies while detatching the
radioactivity from their pharmacokinetic drawback.

iv

Herein, we discuss the in vitro, in vivo, and therapeutic establishment of pretargeted
radioimmunotherapy (PRIT) based on the IEDDA reaction in a pancreatic ductal adenocarcinoma
and colorectal cancer mouse model. Dosimetry caluclations were performed and strategies for the
dosimetric optimization are suggested. The PRIT approach presented here can be applied to other
disease models and has the potential to further advance the use of pretargeted radiotherapy in the
clinic.
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Chapter 1:
1.1

Introduction

Radioimmunotherapy
The concept of a “magic bullet” is one first proposed by Paul Ehrlich in the 1900’s. His

idea was simple: that there could exist a tool that would specifically target and treat disease, much
like a bullet firing from a gun to hit a specific target.1 While there have been many “magic bullets”
in medicine, monoclonal antibodies (mAbs) are of particular interest because of their exquisite
specificity and selectivity for their antigens and the range of antibodies available. The first instance
of attaching radioactivity to an antibody vector was carried out in 1950, where live cell tracking
was successful by monitoring the presence of radioactivity.2 In the years since, the coupling of an
antibody vector to a cytotoxic radionuclide has been used as a method of effective cancer therapy
and is known as radioimmunotherapy (RIT).
Antibodies are proteins generated by white blood cells after exposure to a foreign pathogen.
Antibodies produced by an individual B-cell clone all contain the same antigen-binding region.
The reversible binding of an antibody to its antigen is determined by many weak non-covalent
forces such as hydrogen bonds or Van der Waals forces, which contribute to the affinity of an
antibody-antigen system.3 The affinity is therefore a measure of the sum of these forces and is
independent of the number of antigen binding sites present on the antibody. It is determined by
measuring the amount of antigen necessary to bind one-half of the antibody binding sites and
affinity constants can range from 104 to 1011 M-1.3 While there are a plethora of antibody-antigen
systems available, careful selection of high affinity and high abundance antigen must be used in
order for successful targeting for RIT approaches.
RIT has most widely been used to treat soft, radiosensitive tumors in the clinic, namely
leukemias and lymphomas.4 Solid tumors are generally more radioresistant, requiring about 5–10

times the deposited radiation dose for effective tumor response, or roughly 10,000 cGy.5 Two
radioimmunoconjugates in particular have been successful and gained approval by the United
States Federal Drug Administration (US-FDA) in the early 2000’s for the treatment of NonHodgkin Lymphoma:

90

Y-ibritumomab tiuxetan ("Zevalin") and

131

I-tositumomab (“Bexxar”).

These antibody-based pharmaceuticals are labeled with long-lived radioisotopes (131I, 8.0 days;
90

Y, 2.7 days) which correspond with the long biological half-life of antibodies, ensuring that

enough radioactivity remains by the time the vector reaches its optimal biodistribution. The long
circulation of antibodies poses a potential risk when a therapeutic radionuclide is attached: delivery
of non-target radiation dose to healthy organs en route. Potential strategies to limit this occurrence
will be discussed within this dissertation.

1.2

Radiobiology of Alpha and Beta Particles
When a nucleus is unstable it can release excess energy through emitted particles, the main

3 being: alpha particles, beta particles, and gamma rays. The two main types of radioactive decay
that are suitable for clinical radiotherapy are alpha and beta decay. Alpha particles are charged
helium nuclei that are approximately 8,000 times larger than β-particles. This size distinction
results in a significant difference of their linear energy transfer (LET) or amount of energy
deposited per unit area. Alpha particles have the potential to induce the greatest damage to
surrounding cells because of their high linear energy transfer, whereas beta particles disperse their
energy over a longer path length (Figure 1.1). The longer path length of the beta particle allows
for more distant cells to be affected that are not necessarily reached by the antibody. This is termed
the crossfire effect and can be helpful when treating larger tumors.6 Typically, the range of alphaparticles in tissue is 50-100 µm with a mean energy transfer of 50-230 keV/µm while beta particles
2

travel an average of 275 µm in tissue with a mean LET of 0.2 keV/µm.7 Nuclides emitting either
type of particle have been shown effective when conjugated to a wide range of immunoglobulins
for a number of diseased states.8-10 The short range of alpha particles make them especially potent
for diffuse cancers of lymphatic or hematologic origin where the crossfire effect would only serve
to harm radiosensitive tissue, such as red marrow. Beta particles on the other hand are well suited
to treat larger tumors as their path length allows them to irradiate cancerous cells further from the
decay event.11, 12

Figure 1.1 Track length of alpha-particles and beta-particles relative to cell diameter. Alpha
particles can travel a few cell diameters while beta-particles can travel up to one hundred cell
diameters. Reprinted with permission from Springer Nature: Springer Nature, Nature Reviews
Clinical Oncology, Clinical Radioimmunotherapy – The Role of Radiobiology, Pouget, J. P.; et.
al. Copyright 2011 Springer Nature.4
Radioimmunotherapy elicits a cytotoxic effect primarily though damage to deoxyribonucleic
acid (DNA) in two main ways: 1) Direct ionization in the form of double or single strand breaks
on the DNA structure, 2) indirect damage through the production of reactive oxygen species which
then cause DNA breaks. Not surprisingly, the main form of DNA damage elicited is a function of
the type of radioactive emission, as well as the energy of the particle. Lower energy beta particles
3

can travel further distances, depositing their energy uniformly along the way. This leads to the
production of reactive oxygen species and mostly single-strand breaks (Figure 1.2A). Alpha
particles deposit all of their energy in a short range resulting in mostly double strand breaks to the
DNA (Figure 1.2B). This is the reason for their efficacy at eradicating cells when targeted to
disease tissue.

Figure 1.2 Patterns of cellular damage caused by radiation sorted by LET. A) Beta-emitting
radionuclides with low LET result in sparse ionizations mostly single strand breaks; B) Alpha
emitting nuclides produce dense ionizations along their path length resulting in double strand
breaks that are poorly repairable. Reprinted with permission from Springer Nature: Springer
Nature, Nature Reviews Clinical Oncology, Clinical Radioimmunotherapy – The Role of
Radiobiology, Pouget, J. P.; et. al. Copyright 2011 Springer Nature.4
1.3

Click Chemistry and the IEDDA reaction
Click Chemistry is a term coined by Sharpless and Kolb in 2001 to describe a subset of

chemical reactions. The criteria for a reaction to be deemed “click chemistry” include parameters
such as specificity, modularity, regioselectivity, no byproducts, and high yield.13 Since the
4

emergence of click chemistry, much work has gone into developing this chemistry towards in
vivo biomolecule labeling. Two of the most notable click reactions are the copper catalyzed
azide-alkyne cycloaddition and the strain promoted azide-alkyne cycloaddition, which are great
for synthetic strategies but suffer for in vivo application because of copper toxicity or slow
kinetics, respectively.14-18 A third click reaction of interest for bioconjugations is the inverse
electron demand Diels-Adler (IEDDA) reaction that occurs between an electron deficient
tetrazine diene and an unsaturated olefin dienophile (Figure 1.3).19 This reaction meets all the
criteria set by Sharpless and Kolb, and in addition do not react with any other biological
molecule in vivo, and thus are considered bioothogonal. Once in contact with each other, whether
in vitro or in vivo, they undergo a [4 + 2] cycloaddition giving dihydropyridazine products with
N2 released as the only byproduct.19

Figure 1.3 The inverse electron demand Diels-Alder (IEDDA) reaction between a 1,2,4,5-tetrazine
and trans-cyclooctene resulting in a covalent linkage with the only byproduct N2.

The first occurrence of the inverse electron demand Diels-Adler reaction between tetrazineTCO for bioconjugation was published by Blackman and Fox in 2008. The fast pharmacokinetics

5

(k2 2000 M−1 s−1 in 9:1 methanol/water) of the reaction was established as well as the compatibility
of the ligation with proteins.20 Shortly after, Deveraj et al. published on the utilization of the
IEDDA for in vitro cell labeling.21 In this communication they synthesized a new, more stable
benzylamine-modified tetrazine and tested its reactivity in vitro with a norbornene labeled
antibody. Fluorescence microscopy showed the co-localization of the fluorescently-labeled
tetrazine imaging agent and norbornene-modified antibodies on the surface of live cells. This study
was the first instance of biorthogonal pretargeting of live cells using the inverse electron demand
Diels-Alder reaction. It has been established previously that the reaction kinetics of tetrazines with
highly strained alkenes are exceptionally fast.22 Deveraj took advantage of this fact and used the
more highly strained trans-cyclooctene in conjunction with his benzylamine-modified 1,2,4,5tetrazine and determined a second-order rate constant of 6000± 200 M-1s-1 at 37°C.23 To further
optimize the IEDDA reaction conditions, Karver et al. explored a series of tetrazines and ultimately
determined an inverse relationship between reaction rate and chemical stability.24 We have seen
that there is an intricate balance to be achieved when utilizing the IEDDA reaction, from choosing
the click chemistry partners, to choosing the targeting vector and even the timing intervals in
between. We begin to see now that the work done thus far has only scratched the surface of what
is ultimately possible.

1.4

Pretargeted Imaging and Therapy
Pretargeting is particularly advantageous for nuclear imaging and therapy as it affords a

way to decrease the radiation dose to healthy organs and to the patient. It does so by separating
administration of the targeting vector, that may have a long biological half-life, from injection of
the radioactivity which then combine in vivo. More specifically, pretargeting strategies typically
6

employ two steps: (i) the administration of an antibody capable of binding both an antigen and
small molecule radioligand; (ii) the administration of the small molecule radioligand that binds to
the tumor-bound antibody, followed by the rapid clearance of any excess radioligand (Figure 1.4).
An additional step administered between the two sometimes adds the use of a clearing or masking
agent, and will be discussed further in Chapter 4.

Figure 1.4 Schematic of pretargeting based on the IEDDA. This diagram was originally published
in JNM. Mohamed Altai et al. J Nucl Med 2017; 58:1553-1559.25

There are several approaches to pretargeting, most notably the use of bispecific antibodies,
the intrinsic affinity between streptavidin and biotin, complementary binding of oligonucleotides,
and biorthogonal click chemistry (Figure 1.5).26-30 While each method has its own intrinsic benefits
and downsides, such the immunogenicity of streptavidin, all have shown promise in preclinical
experiments. We focus on pretargeting based on biorthogonal click chemistry where a TCO-

7

modified antibody is injected before administration of a Tz-radioligand, for the remainder of this
dissertation.

Figure 1.5 Four principal mechanisms of in vivo pretargeting. This diagram was originally
published in JNM. Mohamed Altai et al. J Nucl Med 2017; 58:1553-1559.25

The first in vivo proof-of-concept study was conducted by Rossin et al. in which a TCOmodified antibody (CC49-TCO) was injected into mice bearing TAG72-expressing colorectal
cancer xenografts, and 24 hours later

111

In-labeled DOTA-tetrazine was administered for

SPECT/CT imaging.30 Tumor uptake was determined by SPECT analysis as 4.2 % injected dose
per gram (%ID/g) and a tumor-to-muscle ratio (T/M) of 13.1 was calculated. This study
demonstrates that pretargeting based on the IEDDA reaction is effective in vivo at localizing
radioactivity at the tumor site with a reaction rate constant as high as 2.7 × 105 M–1 s–1 under low
concentrations. Since its initial publication, Rossin et al. have led the way in further optimizations
of the IEDDA reaction, investigating areas such as alternative trans-cyclooctene moieties31, 32,
tetrazine-bearing clearing agents31, and antibody fragments as targeting vectors for pretargeting.25,
33

8

Pretargeted PET imaging utilizing the click IEDDA reaction has also been established in
2013 by Zeglis and co-workers.34 A proof-of-concept system comprised of a TCO modified huA33
antibody and a NOTA-conjugated tetrazine radiolabeled with 64Cu yielded PET images showing
clear delineation of colorectal cancer tumors (4.1 ± 0.3 %ID/g) as early as 12 hours after
radioligand administration. These results were further improved in 2015 by optimizing the
tetrazine bearing ligand to yield desired pharmacokinetics and clearance route.35 The new ligand,
Tz-SarAr afforded much higher tumor uptake in a shorter interval (5.6 ± 0.7 %ID/g at 1 h p.i.) and
clearance through the renal system opposed to the gastrointestinal tract. Importantly, the radiation
dosimetry was calculated and compared to the traditional

89

Zr-DFO directly labeled antibody

construct. The overall effective dose was reduced 30-fold from 0.4162 to 0.0124 mSv/MBq, a
figure greatly supporting one of the main benefits of the pretargeting strategy.
Investigations to determine if these results would translate for therapeutic applications were
conducted as early as 2013, where Rossin et. al. used a

177

Lu-tetrazine as the click partner in

preliminary biodistribution studies.36 They found a tumor uptake of 5.38 ± 0.5 %ID/g at 3 hours
post injection of radioligand demonstrating the potential of pretargeted radioimmunotherapy
PRIT. In 2016, Houghton et al. conducted the first in vivo longitudinal PRIT study utilizing the
IEDDA reaction.37 The experimental design and results will be discussed in detail in the next
chapter.
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Chapter 2:

Pretargeted Radioimmunotherapy of Pancreatic Cancer

Disclaimer: Adapted with permission from Houghton, J.L.; Membreno, R.; Abdel-Atti, D.;
Cunanan, K. M.; Carlin, S.; Scholz. W. W.; Zanzonico, P. B.; Lewis, J. S.; Zeglis, B. M.
Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse
Electron

Demand

Diels-Alder

Click

Chemistry.

Molecular

Cancer

Therapeutics,

2017, 16, (1), 124-133. Copyright 2017 American Association for Cancer Research.37

2.1

Introduction
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers,

is the fourth leading cause of cancer-related deaths worldwide.38 PDAC is one of the most
aggressive cancers with high metastatic potential, leading to a five-year survival rate of around 5–
7%.39 Pancreatic cancer is rare before the age of 40, with a median age at diagnosis of 73 years.
The grim prognosis of PDAC is mainly due to a deficiency in reliable biomarkers for early
diagnosis as well as a lack of visible and distinctive symptoms, resulting in delayed diagnosis and
limiting effective therapy.40 The only curative option is surgical resection of the pancreas, however
this option is only available to the 20% of patients who were diagnosed at an early enough stage.41
It is therefore critical to find biomolecular markers to allow for earlier diagnosis and more targeted
treatment options.
Carbohydrate Antigen 19.9 (CA19.9) is a sialylated Lewis blood group antigen whose
overexpression is indicative of the occurrence and metastasis of many cancers, including PDAC,
and is a very promising candidate for earlier detection methods.42, 43 As a result, fully human
monoclonal antibodies with high affinity for CA19.9 were developed for diagnostic and
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therapeutic applications.44 Of particular interest is the 5B1 fully human antibody which binds an
extracellular epitope of CA19.9 with low nanomolar affinity and has been previously shown to
yield high tumoral uptake in immunoPET studies of preclinical models of PDAC.45,

46

Interestingly, the CA19.9 antigen has a propensity to shed from the tumor site which makes it a
viable serum biomarker but presents a challenge for radiolabeled antibody imaging strategies. One
investigation demonstrated that a preinjection of “cold” or unmodified 5B1 antibody prior to
injection of [89Zr]Zr-DFO-5B1 would bind circulating CA19.9 thus provide better image
contrast.47 [89Zr]Zr-DFO-5B1 is currently undergoing a phase 1 clinical trial (NCT02687230)
under the drug name MVT-2163.
In addition to shed antigen, internalization upon binding of the antibody is also observed
in several models of pancreatic cancer.44 This presents an even more troubling situation for
pretargeted strategies where the surface bound 5B1-TCO conjugate is the “beacon” to which the
radioligand binds. Internalization of the 5B1-bound antigen serves to obscure the reactive TCO,
and prevents radioligand binding. In light of this obstacle, Houghton et al. investigated the
pharmacokinetics of the radioligand, [64Cu]Cu-NOTA-PEG7-Tz, as well as rates of internalization
of CA19.9 in several cell lines.48 They found that the addition of a PEG linker in the Tzradioligand affords the same high tumor uptake but significantly faster clearance in background
organs, resulting in clear tumor delineation as early as 6 hours post injection of radioligand.
Although 5B1-CA19.9 structures were found to rapidly internalize, pretargeted PET imaging still
resulted in high tumor uptake of 8.2 ± 1.7 %ID/g at 20 hours post injection using a 72-hour
antibody accumulation interval. To further support the pretargeting concept, dosimetry was
calculated and compared to the clinical candidate [89Zr]Zr-DFO-5B1. Total radiation absorbed
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dose using the pretargeting system was reduced greater than 25-fold over directly labeled 5B1 and
at least a 15-fold reduction was observed for each tissue.48
With successful pretargeted PET imaging studies in hand, the next step was to investigate
the efficacy of a therapeutic strategy utilizing the 5B1 antibody and CA19.9. To that end we
investigated

177

Lu-Tz radioligands paired with a TCO-labeled 5B1 antibody, a strategy that will

be discussed in this chapter.

2.2

Synthesis of Tz-bearing Ligands
The syntheis and characterization of DOTA-PEG7-Tz and CHX-A″-DTPA-PEG7-Tz were

prepared via a three-step synthesis (Figure 2.1). First, Benzylamino tetrazine Nhydroxysuccinimidyl ester (Tz-NHS) was reacted with a Boc-protected amino PEG7 to form Boc
protected Tz-PEG7-NHBoc. Next, this intermediate was deprotected in a mixture of trifluoroacetic
acid (TFA) in dichloromethane (DCM) to form Tz-PEG7-NH2. Lastly, this amine containing
molecule was conjugated to the chelator by attachment at the p-isothiocyanate of DOTA-NCS or
CHX-A″-DTPA-NCS to yield the products; Tz-PEG7-DOTA and Tz-PEG7-CHX-A″-DTPA. All
products and intermediates were characterized by 1H-NMR,
resolution mass spectrometry (Supporting Information).
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C-NMR, ESI-MS, and high-

Figure 2.1 Synthesis scheme of Tz-PEG7-DOTA and Tz-PEG7-CHX-A″-DTPA.

2.3

Radiolabeling of Tz-bearing Ligands
Radiolabeling of the ligands was facile and resulted in high radiochemical purity (>95%).

First, an ammonium acetate buffer (0.25 M, pH 5.5, 200 µL) was prepared. Tz-PEG7-DOTA or
Tz-PEG7-CHX-A″-DTPA (9.6 µg, 0.8 nmol or 13 µg; 0.78 nmol, respectively) was added to the
buffer and incubated with the desired amount of [177Lu]LuCl3 in 0.1 M HCl (300 - 5000 µCi, 11.1
– 185 MBq). [177Lu]LuCl3 was obtained from the research reactor at The University of Missouri
where it is produced from Lu-176 targets with a final specific activity of ≤ 25 Ci/mg. The reaction
mixture was then placed on an agitating thermomixer at 37°C for 10 min at 300 rpm. After this
incubation, the progress of the radiolabeling was determined by iTLC using 50 mM EDTA pH 5.5

13

as the mobile phase, which revealed quantitative labeling of >95 radiochemical purity, thus no
further purification was deemed necessary. The final specific activity of [177Lu]Lu-CHX-AʺDTPA-PEG7-Tz was 307.6 µCi/µg; (molar activity: 383.3 mCi/µmol; 14.2 GBq/µmol; n = 1).
The final specific activity of [177Lu]Lu-DOTA-PEG7-Tz was 387.1 ± 129 µCi/µg (molar activity:
466.1 ± 155 mCi/µmol; 17.2 ± 5.7 GBq/µmol; n = 4).

2.4

In Vitro Stability Study
A stability study was then performed to determine the percent sequestration of the metal in

the radioligand under different conditions. Samples of [177Lu]Lu-DOTA-PEG7-Tz or [177Lu]LuCHX-Aʺ-DTPA-PEG7-Tz (1000 µCi) were incubated on an agitating thermomixer (300 rpm) at
37 °C in 500 µL of either PBS (pH 7.4) or human serum. At each prescribed time-point, 100 µL
of the solution was removed and placed into a 1.7 mL microcentrifuge tube. For the PBS samples,
the solution was directly analyzed via radio-iTLC with 50 mM EDTA pH 5.5 used as the mobile
phase. For the serum samples, 100 µL cold CH3CN was added to precipitate the proteins, and the
resultant mixture was vortexed and centrifuged at 10,000 rpm for 10 min. The resulting clear
supernatant was then analyzed via radio-iTLC. The residual protein pellet from the centrifuge spins
was checked for radioactivity, and only minimal residual activity remained. The fraction of intact
[177Lu]Lu-DOTA-PEG7-Tz or [177Lu]Lu-CHX-Aʺ-DTPA-PEG7-Tz was determined by integrating
the peak appearing at the baseline, corresponding to intact ligand. Free 177Lu metal traveled with
the solvent front and appeared at an Rf of 1.0. All experiments were performed in triplicate.
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Table 2.1 Stability of [177Lu]Lu-DOTA-PEG7-Tz and [177Lu]Lu-CHX-Aʺ-DTPA-PEG7-Tz in PBS
and human serum over time. Measurements were obtained via iTLC and a developing solvent of
50 mM EDTA pH 5.5.

2.5

Partition Coefficient (LogD) Studies
The partition coefficient is a measure of the lipophilicity of the ligand which gives us an

idea of the ligands’ solubility, pharmacokinetics and clearance in vivo. To this end, [177Lu]LuDOTA-PEG7-Tz or [177Lu]Lu-CHX-Aʺ-DTPA-PEG7-Tz (1 µCi) was added to a mixture of 3 mL
PBS (pH 7.4) and 3 mL 1-octanol. The resulting mixture was then vortexed thoroughly for 1
minute and subsequently centrifuged at 1,000 rpm for 10 min. 1 mL of each layer (PBS and 1octanol) was then collected and separated, and the amount of radioactivity in each sample counted
on a gamma counter calibrated for 177Lu. The partition coefficient (logD) was calculated using the
formula:
LogD = log10[(counts per minuteoctanol)/(counts per minutePBS]
All experiments were performed in triplicate.
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Table 2.2 Partition coefficients of of [177Lu]Lu-DOTA-PEG7-Tz and [177Lu]Lu-CHX-Aʺ-DTPAPEG7-Tz.

2.6

In Vivo Xenograft Model
To grow our tumor models, female athymic nude mice, strain Crl:NU(NCr)- Foxn1nu

(Charles River Laboratories, Wilmington, MA) age between 6-8 weeks were xenografted
subcutaneously (cells implanted directly under the skin either at the flank or shoulder site) with 5
x 106 BxPC3 cells (pancreatic cancer cell line), suspended in 150 µL of a solution containing a 1:1
mixture of Matrigel and cell culture medium. Tumors were grown for 21-28 days postimplantation prior to imaging or biodistribution.

2.7

Biodistribution Studies
Initial biodistribution studies to compare the in vivo behavior of the two ligands were

conducted using a CA19.9 positive BxPC3 subcutaneous xenograft model. Mice were randomized
into groups and warmed gently using a heat lamp to cause swelling of the lateral tail vein prior to
being administered 5B1-TCO (200 µg in 200 µL of 0.9% saline). After 72 hours, the mice were
injected with [177Lu]Lu- DOTA-PEG7-Tz- or [177Lu]Lu- CHX-A˝-DTPA-PEG7-Tz (250 - 300 µCi;
9.25 - 11.1 MBq). At the appropriate time post injection, mice were euthanized via asphyxiation
16

using CO2(g) and 13 tissues including the tumor were collected and placed into pre-weighed tubes.
The mass of each organ was determined and then each sample was counted using a Wizard2
automatic gamma counter calibrated for

177

Lu. A calibration curve generated from standards of

known activity was used to convert counts into activity. The counts from each sample were decayand background-corrected from the time of injection, and the activity in each sample was then
converted to %ID/g by normalization to the total activity injected into the respective animal and
the weight of the organ.
When comparing both ligands, we can see that Tz-PEG7-DOTA afforded higher tumor
uptake over Tz-PEG7-CHX-A˝-DTPA (Figure 2.2). Additionally, Tz-PEG7-CHX-A˝-DTPA has
higher retention in the kidneys as a result of its clearance. The LogD and stability of both ligands
are comparable leading us to believe that the macrocyclic nature of the DOTA chelator as well as
the overall charge is the reason for the superior biodistribution. It has been observed that a lower
net charge on the radioligand is correlated with a longer plasma half-life which may account for
the higher tumoral uptake observed with the DOTA ligand (-1 charge on DOTA ligand vs -2 charge
on DTPA ligand).49 As a result of these initial studies, Tz-PEG7-DOTA was chosen for all future
studies including a more thorough biodistribution and longitudinal therapy study.
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Figure 2.2 Initial biodistribution results 177Lu-Tz ligands with a 72hr preinjection of 5B1-TCO in
nude mice bearing subcutaneous BxPC3 xenografts. A) [177Lu]Lu-DOTA-PEG7-Tz or
B)[177Lu]Lu-CHX-Aʺ-DTPA-PEG7-Tz was used as the radioligand (n = 5 per timepoint).

To that end, mice bearing BxPC3 xenografts were injected with 5B1-TCO (200 µg, 1.3
nmol in 200 µL of 0.9% saline) 72 hours prior to administration of [177Lu]Lu-DOTA-PEG7-Tz
(300 µCi, 11.1 MBq; 2 nmol) . At prescribed time points organs were harvested, dried in open air
for 5 minutes, and placed in pre-weighed culture tubes. The harvested organs were re-weighed and
counted for activity on a gamma counter calibrated for 177Lu. The counts from each sample were
decay- and background-corrected from the time of injection, and the activity in each sample was
then converted to %ID/g by normalization to the total activity injected into the respective animal
and the weight of the organ.
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Figure 2.3 Biodistribution data obtained from an in vivo pretargeting experiment in which
[177Lu]Lu-DOTA- PEG7-Tz (11.1 MBq, 2 nmol) was injected 72 h after the administration of 5B1TCO (1.3 nmol). The activity concentrations in selected tissues at time points ranging from 4 to
120 h after the injection of [177Lu]Lu-DOTA-PEG7-Tz were determined along with selected tumorto-tissue activity concentration ratios (inset).

Results confirm the high tumor uptake and more importantly long retention in tumor tissue
using the pretargeting system 5B1-TCO and [177Lu]-DOTA-PEG7-Tz with a 72 hour preinjection
interval (Figure 2.3). Clearance from non-target tissues was rapid and led to promising tumor-tonormal tissue activity concentration ratios at 120 h (Figure 2.3 inset). The next step for the PRIT
investigation was to conduct an in vivo longitudinal therapy study. To aid us in determining the
radioactive dose to administer, dosimetry was calculated for a murine model.
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2.8

Dosimetry

The dosimetry estimates in a murine model suggest that our PRIT approach efficiently delivers
cytotoxic radiation to the tumor without causing significant toxicity to background organs (
Table 2.3). In preclinical studies, a dose of approximately 10,000 cGy is needed to be delivered to
the tumor for successful therapy. Our dosimetry estimates that 20,571 rads per mCi is delivered to
the tumor. This corresponds to a radioactive dose of 486 µCi that would need to be administered
in order to elicit a therapeutic response. Thus doses of 400, 800, and 1200 µCi were chosen for the
therapy study to view the range of therapeutic efficacy and if a dose-dependent response is

observed.

Table 2.3 Dosimetry calculations for a mouse model using [177Lu]Lu-DOTA-PEG7-Tz + 5B1-TCO
PRIT based on biodistribution data from the 72 hour preinjection.
20

2.9

Longitudinal Therapy Study
Mice bearing established BxPC3 subcutaneous tumors (mean tumor volume 150 ± 50 mm3)

were randomly sorted into 5 groups of 8 mice per group. In order to see the therapeutic window of
the pretargeted methodology, the treatment groups received injections of the radioligand loaded
with 400, 800, or 1200 µCi via the lateral tail vein 72 h after administration of 5B1-TCO (200 µg
in 200 µL of 0.9% saline). The remaining two cohorts served as control groups, receiving either
saline or 1200 µCi of [177Lu]Lu-DOTA-PEG7-Tz. Neither control group was administered 5B1TCO. All mice were weighed, and the tumor burden was assessed by caliper measurement every
3-4 days until day 17, and then every 7 days thereafter until the conclusion of the experiment. Mice
were sacrificed if the tumor grew to >1.0 cm3 or if the mouse lost >20% of its body mass during
the course of the study.
In vivo studies using PRIT demonstrated a clear dose dependent response, with regression
in tumor volume occurring the the cohorts receiving the highest dose of radioligand (Figure 2.4).
Interestingly, the dose determined by the dosimetry calculations was only able to delay tumor
progression, not cause regression. Admittedly, the dose administered was slightly lower than the
calculations prescribed (400 vs 486 µCi) but nonetheless a dose of approximate twice the
calculated amount was necessary to view regression. Future therapy studies will evaluate a larger
window in dose range and its effect on tumor response. Naturally, the control groups grew steadily
as one would expect from the BxPC3 cell line, illustrating the fact that the PRIT strategy required
both partners to be effective.
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Figure 2.4 Graphs depicting tumor volume over time following pretargeted treatment consisting
of a 72 hour preinjection of 5B1-TCO followed by varying doses of [177Lu]Lu-DOTA-PEG7-Tz A)
Average tumor volume of each group over time; B) Normalized tumor volume to day one volumes
of each group over time (n = 8 per cohort).
2.10 Conclusion
In summary, we successfully demonstrated pretargeted radioimmunotherapy in a murine
model of pancreatic cancer. DOTA-PEG7-Tz was chosen as the optimal ligand for our studies due
to its superior biodistribution profile. Dosimetry calculations confirmed effective irradiation to the
tumors with low doses to healthy organs, supporting our PRIT approach. Additionally, dosimetry
allowed for the development of a treatment plan for the in vivo longitudinal therapy study. The
results of said study demonstrated a clear dose dependent response in tumor volume in the
treatment cohorts, while control cohorts grew without hindrance illustrating that both click partners
were necessary for treatment. The next step for PRIT is the translation of this technology to
different disease models and further dosimetric optimizations.
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2.11 Supporting Information
2.11.1 Synthesis of Tz-PEG7-NHBoc
Tz-PEG7-NHBoc

(tert-butyl

(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7-dioxo-

11,14,17,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)carbamate)
previously described
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was

prepared

as

. Tz-NHS (10 mg; 0.025 mmol; 398.4 g/mol) was dissolved in 400 µL

DMSO and added to 15 mg O-(2-aminoethyl)-O’-[2-(bocamino)ethyl]hexaethylene glycol (0.032
mmol; 1.3 equiv.; 468.6 g/mol). To this solution, 10 µL triethylamine (7.3 mg; 0.072 mmol; 101.2
g/mol) was then added, and the solution was placed on a thermomixer at 300 rpm at 25 °C. After
30 minutes, the reaction was purified via preparative C18 HPLC using a gradient of 5:95
CH3CN:H2O (both with 0.1% TFA) to 95:5 CH3CN:H2O over 30 min (tR = 18.2 min).
Lyophilization of the HPLC eluent yielded the purified product as 16 mg of a bright pink powder
(MW = 751.9 g/mol; 0.021 mmol; 85% yield). 1H NMR (500 MHz, DMSO), δ, ppm: 10.52 (s,
1H), 8.50 (m, 3H), 7.82 (t, 1H), 7.46 (d, 2H), 6.69 (t, 1H), 4.33 (d, 2H), 3.42 (m, 22H), 3.33 (t,
2H), 3.31 (t, 2H), 3.12 (q, 2H), 2.99 (q, 2H), 2.12 (t, 2H), 2.03 (t, 2H), 2.12 (t, 2H), 1.70 (q, 2H),
1.29 (s, 9H). ESI-MS(+): m/z (%) = 753.1 [M+H]+ HRMS (ESI): m/z calcd. for C35H57N7O11Na:
774.4005; found: 774.4014. UV-Vis: ε525 = 530 M-1cm-1.

2.11.2 Synthesis of Tz-PEG7-NH2
Tz-PEG7-NH2

[N1-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-N5-(23-amino-3,6,9,12,15,18,21-

heptaoxatricosyl)glutaramide] was prepared as previously described
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. Tz-PEG7-NHBoc (1, 10

mg; 0.014 mmol; 717.5 g/mol) was first dissolved in 400 µL of 1:1 CH2Cl2:TFA and placed on an
agitating thermomixer at 300 rpm for 30 minutes at 25 °C. After 30 minutes, the solvent was
removed via rotary evaporation, the residue was taken back up in H2O, and the reaction was
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purified via preparative C18 HPLC using a gradient of 5:95 CH3CN:H2O (both with 0.1% TFA) to
95:5 CH3CN:H2O over 30 min (tR = 12.5 min). Lyophilization of the HPLC eluent yielded the
purified product as 9 mg of a bright pink powder (MW = 651.7; 0.013 mmol; 95% yield). 1H NMR
(500 MHz, DMSO), δ, ppm: 10.58 (s, 1H), 8.46 (m, 2H), 7.87 (t, 1H), 7.75 (d, 2H), 7.52 (d, 1H),
4.40 (d, 2H), 3.60-3.50 (m, 26H), 3.40 (t, 2H), 3.32 (bs, 2H), 3.20 (q, 2H), 2.99 (bs, 2H), 2.19 (t,
2H), 2.12 (t, 2H), 1.79 (q, 2H). ESI-MS(+): m/z (%) = 652.9 [M+H]+ HRMS (ESI): m/z calcd. for
C30H50N7O9: 652.3670; found: 652.3676. UV-Vis: ε525 = 535 M-1cm-1.’

2.11.3 Synthesis of DOTA-PEG7-Tz
DOTA-PEG7-Tz

[2,2',2'',2'''-(2-(4-(3-(1-([3,3'-bi(1,2,4,5-tetrazin)]-6-yl)-3,7-dioxo-

11,14,17,20,23,26,29-heptaoxa-2,8-diazahentriacontan-31-yl)thioureido)benzyl)-1,4,7,10tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid] was prepared as previously described 37.
A portion of Tz-PEG7-NH2 (2, 11.5 mg; 0.0176 mmol; 652.4 g/mol) was dissolved in 400 µL
DMSO and added to 14.8 mg p-SCN-BN-DOTA (0.0022 mmol; 1.2 equiv.; 688.0 g/mol). 20 µL
triethylamine (14.8 mg; 0.15 mmol; 101.2 g/mol) was then added to this solution, and the solution
was placed on an agitating thermomixer at 300 rpm for 60 minutes at 25 °C. After 60 minutes, the
reaction was purified via preparative C18 HPLC using a gradient of 5:95 CH3CN:H2O (both with
0.1% TFA) to 95:5 CH3CN:H2O over 30 min (tR = 20.7 min). Lyophilization of the HPLC eluent
yielded 15.4 mg of purified product as a bright pink powder (MW = 1203.4; 0.0128 mmol; 72.7%
yield). 1H NMR (500 MHz, DMSO), δ, ppm: 10.57 (s, 1H), 9.63 (bs, 1H), 8.45 (m, 3H), 7.86 (m,
1H), 7.73 (bs, 1H), 7.54 (d, 2H), 7.41 (m, 2H), 7.19 (m, 2H), 6.54 (bs, 1H), 4.40 (d, 2H), 4.003.20 (m, 55H), 3.20 (q, 4H), 2.54 (s, 1H), 2.18 (t, 3H), 2.10 (t, 3H), 1.76 (q, 2H). ESI-MS(-): m/z
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(%) = 1203.0 [M-H]-; 601.8 [M-2H]2- HRMS (ESI): m/z calcd. for C50H76N11O15S: 1202.56; found:
1203.5741.

2.11.4 Synthesis of Tz-PEG7-AF680
A portion of Tz-PEG7-NH2 (1 mg; 0.0015 mmol; 651.8 g/mol) was dissolved in 400 µL
DMSO and added to 2 mg AF680-NHS (.0021 mmol; 1.4 equiv.; 955.9 g/mol). 10 µL
triethylamine (7.3 mg; 0.072 mmol; 101.2 g/mol) was then added to this solution, and the solution
was placed on an agitating thermomixer at 300 rpm for 30 minutes at 25 °C. After 30 minutes, the
reaction was purified via preparative C18 HPLC using a gradient of 5:95 CH3CN:H2O (both with
0.1% TFA) to 95:5 CH3CN:H2O over 30 min (tR = 11.2 min). Lyophilization of the HPLC eluent
yielded the purified product, [3-(2-((1E,3E)-5-((Z)-3-(1-(4-(1,2,4,5-tetrazin-3-yl)phenyl)-3,7,33trioxo-11,14,17,20,23,26,29-heptaoxa-2,8,32-triazaoctatriacontan-38-yl)-3-methyl-5-sulfo-1-(3sulfopropyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-5-bromo-3,3-dimethyl-3H-pyrrolo[2,3b]pyridin-7-ium-7-yl)propane-1-sulfonate], as a 2 mg of a deep blue powder (MW 1492.6; 0.0013
mmol; 79% yield).

2.11.5 Preparation of 5B1-TCO
An aliquot of 5B1 (1.6 mg, 10.7 nmol) was dissolved in 500 µL of phosphate buffered
saline (PBS, pH 7.4), and the pH of the solution was adjusted to 8.8 - 9.0 with Na2CO3 (0.1 M). A
volume of TCO-NHS in DMF (25 mg/mL) was added to yield a TCO-NHS: 5B1 reaction
stoichiometry of 40: 1. The resulting solution was incubated at 25 °C for 1 hour with shaking at
400 rpm. After 1 hour, the modified antibody was purified using size-exclusion chromatography
(Sephadex G-25M, PD-10 column, GE Healthcare; dead volume = 2.5 mL, eluted with a 2 mL
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fraction of PBS, pH 7.4) and concentrated using centrifugal filtration units with a 50,000 Da
molecular weight cut off (AmiconTM Ultra 2mL, Millipore Corp., Billerica, MA) and PBS (pH
7.4). Final protein concentration was obtained from a Thermo Scientific™ NanoDrop™
spectrophotometer.

2.11.6 Determination of the TCO occupancy of 5B1-TCO
The TCO occupancy of 5B1-TCO was determined as previously described 35, 37. A solution
of 5B1-TCO (100 µg; 0.66 nmol) in 900 µL PBS (pH 7.4) was first prepared (0.74 µM). Next, 100
µL of a 1 mM solution of Tz-PEG7-AF680 in DMSO was added to create a reaction volume of
1000 µL and concentrations of 0.66 µM 5B1-TCO and 100 µM Tz-PEG7-AF680 (a ~150-fold
excess of Tz). This solution was placed on an agitating thermomixer at 300 rpm at 25 °C. After
180 minutes of incubation, the resulting fluorophore-labeled immunoconjugate was purified using
size-exclusion chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare; dead volume
= 2.5 mL, eluted with 2 mL of PBS, pH 7.4) and concentrated by using centrifugal filtration units
with a 50,000 Da molecular weight cut off (AmiconTM Ultra 4, Millipore Corp., Billerica, MA).
The degree of labeling (DOL) was determined by UV-Vis analysis. Absorbance measurements
were taken at 280 nm and 680 nm, and the DOL was calculated using the following formulas:
AmAb = A280 – Amax(CF)
DOL = [Amax*MWmAb]/[[mAb]*εAF680]
where the correction factor (CF) for AF680 was given as 0.05 by the supplier, MWhuA33 = 150,000,
εAF680 = 184,000, and ε280, huA33-TCO = 225,000. Given the rapid and quantitative nature of the
IEDDA reaction, the degree of labeling of AF680 was assumed to be the degree of labeling of
TCO.
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2.11.7 Dosimetry
The biodistribution data for the [177Lu]Lu-DOTA-PEG7-Tz / 5B1-TCO pretargeting
system described in this investigation was expressed as normal-organ mean standard uptake values
(SUVs) versus time post-administration. Assuming, in first order, that SUVs are independent of
body mass and thus the same among species, the mean SUV in mouse organ i, SUVi, was converted
to the fraction of the injected dose in each human organ I, FIDI, using the following formula:
FIDI = SUVi •

MassofHumanOrgan I
MassofHumanTotalBody

These data were decay corrected and fit to exponential time-activity functions. The residence time
€

in a human organ i (ti, in µCi-h/µCi) was calculated by integrating the time-activity function in
organ i, replacing the biological clearance constant, (lb)x for each component, x, of the fitted
exponential function with the corresponding effective clearance constant, (le)x [(le)x = (lb)x + lp,
where lp is the physical decay constant of the radionuclide. The resulting organ residence times
were entered into the OLINDA computer program utilizing the 70-kg Standard Man anatomic
model to yield the mean organ absorbed doses and effective dose in rad/mCi and rem/mCi,
respectively, which were then converted to cGy/MBq.50
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Chapter 3:

Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma

Disclaimer: Reprinted (adapted) with permission from Membreno, R; Cook, B. E.; Fung, K. C.;
Lewis, J.S.; Zeglis, B. M., Click-Mediated Pretargeted Radioimmunotherapy of Colorectal
Carcinoma. Mol. Pharmaceutics, 2018, 15, (4), 1729-1734. Copyright 2018 American Chemical
Society.51

3.1

Introduction
The promise of radioimmunotherapy (RIT) for the treatment of cancer rests in large part

on the exquisite specificity and selectivity of monoclonal antibodies for cancer biomarkers.52 A
critical limitation of this approach, however, stems from the long serum half-lives of antibodies.
Indeed, immunoglobulins can circulate in the blood for days or weeks before reaching their optimal
biodistribution. As a result, radioimmunoconjugates for RIT must be labeled with long-lived
isotopes such as

177

Lu (t1/2 = 6.8 d) or

131

I (t1/2 = 8.0 d) to ensure that significant amounts of

radioactivity remain once the antibody has reached the tumor tissue. Unfortunately, the use of
these long-lived radionuclides presents a significant drawback: high radiation doses to healthy
tissues during the circulation of the radioimmunoconjugate.53
Pretargeted radioimmunotherapy (PRIT) is an alternative approach to RIT that combines
the specificity and affinity of antibodies with the pharmacokinetics of small molecules. In vivo
pretargeting achieves this by decoupling the targeting vector and the radioactivity, administering
the two components separately, and allowing them to combine within the body. A number of
different mechanisms for pretargeting have been explored, most notably the use of bispecific
antibodies, which have had preclinical success and are currently being investigated in clinical
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trials.9, 27 However, due to the complexity and expense of such systems, the creation of more
modular approaches to pretargeting is crucial for its widespread application.
A particulary promising pretargeting strategy that has emerged over the last few years is
based on the rapid and bioorthogonal inverse electron demand Diels-Alder (IEDDA) reaction
between a Tz-bearing radioligand and a TCO-modified antibody (mAb-TCO; Figure 3.1A). In vivo
pretargeting based on the IEDDA reaction typically has four steps: (1) the administration of an
mAb-TCO immunoconjugate; (2) the accumulation of the immunoconjugate at the site of antigen
expression and its concurrent clearance from the blood and non-target organs; (3) the injection of
a Tz-bearing radioligand; and (4) the in vivo click ligation between the two components followed
by the rapid excretion of the radioligand from the bloodstream (Figure 3.1). Pretargeted PET and
SPECT imaging using this approach have proven very effective, producing high quality images at
time points as early as 1 h following the administration of the radioligand.30, 36
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Figure 3.1 (A) The inverse electron demand Diels-Alder (IEDDA) reaction between transcyclooctene and tetrazine; (B) the structure of the [177Lu]Lu-DOTA-PEG7-Tz radioligand; (C)
cartoon schematic of pretargeted radioimmunotherapy based on the IEDDA reaction.

Until recently, the application of the IEDDA reaction to PRIT had not been investigated
beyond preliminary biodistribution data.36 In 2017, however, Houghton et al. performed the first
longitudinal therapy study of

177

Lu-based PRIT in a murine model of pancreatic ductal

adenocarcinoma (PDAC) and produced extremely promising results.37 Herein, we present an
investigation into the efficacy and dosimetry of click-mediated PRIT using a TCO-bearing
immunoconjugate of the huA33 antibody, a 177Lu-labeled Tz radioligand, and a murine model of
A33 antigen-expressing human colorectal carcinoma. We have previously demonstrated the
efficacy of pretargeted PET imaging utilizing the huA33 antibody/antigen system in the same
murine model of colorectal carcinoma.34, 35
30

3.2

HuA33 Antibody System
The huA33 antibody is a humanized antibody that targets the A33 antigen, a

transmembrane glycoprotein present on the surface of >95% of all colorectal carcinomas.54, 55 The
A33 antigen is an extraordinarily promising target for in vivo pretargeting for two reasons. First,
upon binding the A33 antigen, the huA33 antibody persists on the surface of the cell for weeks,
meaning that huA33-TCO immunoconjugate will remain readily available for click ligations with
any incoming Tz-based radioligands.54 Second, while the A33 antigen is most highly expressed in
colorectal cancer cells, it is also expressed at lower levels by the epithelium of healthy small and
large intestines.8, 54 Not surprisingly, this presents a major challenge for traditional RIT. However,
an interesting wrinkle makes it an enticing opportunity for PRIT. To wit, it has been shown that
the A33 antigen is shed from healthy bowel tissue in a few days, while the same antigen is retained
on tumor tissue for weeks.55 It follows that one can imagine a PRIT approach in which the huA33TCO immunoconjugate is injected and provided an accumulation interval time long enough to
allow it to bind its antigen and then shed from healthy tissue while remaining on malignant tissue.
By the time the Tz-based radioligand is injected, the huA33-TCO will only be present at the tumor.
In this way, this strategy could simultaneously increase the specificity of this therapeutic approach
for tumor tissue and limit the radiation dose to the healthy bowel tissue compared to traditional
RIT.
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3.3

Synthesis of Tz-PEG7-DOTA
Due to its effectiveness in previous studies, [177Lu]Lu-DOTA-PEG7-Tz was selected as the

radioligand for this investigation (Figure 3.1B).37 The synthesis of this chelator-bearing precursor
is a facile, modular, three-step procedure. First, a Boc-protected polyethylene glycol linker is
conjugated to the tetrazine-NHS ester via a simple coupling reaction. Next, the intermediate is
deprotected using trifluoroacetic acid in dichloromethane. And finally, the DOTA chelator is
attached through similar chemistry as the first step, and the final product is isolated and purified
via semi-preparative, reversed-phase C18 HPLC in ~74% yield.

3.4

Radiolabeling of DOTA-PEG7-Tz with 177Lu
The radiosynthesis to produce the final product — [177Lu]Lu-DOTA-PEG7-Tz — is also

straightforward: DOTA-PEG7-Tz Tz (5 - 25 µg; 4.1 - 20.7 nmol) in DMSO wass incubated with
[177Lu]LuCl3 (1500−7500 µCi, 55.5-277.5 MBq) in a solution of 0.25 mM NH4OAc (pH 5.5) for
10 minutes at 37 °C. [177Lu]LuCl3 was obtained from the research reactor at The University of
Missouri where it is produced from Lu-176 targets with a final specific activity of ≤ 25 Ci/mg. A
radiochemical yield of > 98% was determined for our radioligand using radio instant thin layer
chromatography (iTLC), and no further purification was necessary prior to administration. The
final molar activity of [177Lu]Lu-DOTA-PEG7-Tz was 17.2 ± 5.7 GBq/μmol; n = 4.

3.5

HuA33-TCO conjugation
The huA33-TCO immunoconjugate was likewise synthesized according a previously

reported protocols.35 An aliquot of huA33 (1.6 mg, 10.7 nmol) was dissolved in 500 µL of
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phosphate buffered saline (PBS, pH 7.4), and the pH of the solution was adjusted to 8.8 - 9.0 with
Na2CO3 (0.1 M). A volume of TCO-NHS in DMF (25 mg/mL) was added to yield a TCO-NHS:
huA33 reaction stoichiometry of 40: 1. The resulting solution was incubated at 25 °C for 1 hour
with shaking at 400 rpm. After 1 hour, the modified antibody was purified using size-exclusion
chromatography (Sephadex G-25M, PD-10 column, GE Healthcare; dead volume = 2.5 mL, eluted
with a 2 mL fraction of PBS, pH 7.4) and concentrated using centrifugal filtration units with a
50,000 Da molecular weight cut off (AmiconTM Ultra 2mL, Millipore Corp., Billerica, MA) and
PBS (pH 7.4). Final protein concentration was determined using a Shimadzu BioSpec-nano Microvolume UV-Vis Spectrophotometer. Determination of the number of TCOs per antibody was
determined through the use of a fluorophore labeled tetrazine, described in detail in section 3.11.4.
It was found that approximately 2-3 TCOs were conjugated per antibody.

3.6

In Vivo Biodistributions
The first in vivo biodistribution experiments were carried out to determine the optimal time

interval between the injection of the huA33-TCO and the administration of the

177

Lu-labeled

radioligand. To this end, athymic nude mice bearing A33 antigen-expressing subcutaneous
SW1222 human colorectal carcinoma xenografts were administered huA33-TCO (100 µg, 0.6
nmol) either 24, 48, or 72 hours prior to the injection of [177Lu]Lu-DOTA-PEG7-Tz (11.1 MBq,
0.7 nmol). At prescribed time points following the administration of the radioligand, select organs
were harvested, weighed, and their activity quantified via gamma counting (Figure 3.2).
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Figure 3.2 Biodistribution in of in vivo pretargeting with huA33-TCO and [177Lu]Lu-DOTAPEG7-Tz in athymic nude mice bearing subcutaneous SW1222 human colorectal cancer tumors
using pretargeting intervals of 24 (purple), 48 (green), or 72 (orange) hours. Data is reported with
standard errors, and a statistical analysis was performed using an unpaired Student’s t test; **p
< 0.01.

The biodistribution data plainly illustrate that excellent tumoral activity concentrations can
be achieved using each of the three pretargeting time intervals, with the highest tumoral activity
concentration (21.2 %ID/g ± 2.9, n = 4) observed using an interval of 24 h. The 24 h interval also
affords the highest tumor-to-background organ activity concentration ratios (Table 3.1). Indeed,
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with this injection interval, the tumor-to-blood, tumor-to-liver, and tumor-to-muscle activity
concentration ratios at 120 h after the administration of the radioligand are 20 ± 5, 37 ± 7, and 184
± 30, respectively. Taken together, these two factors led us to adopt it as the interval of choice for
subsequent longitudinal therapy studies.
We also observed that the uptake of radioactivity in the tumor increases from 4 to 120 h
post-injection, even when the antibody is given 72 h to accumulate at the tumor and clear from the
bloodstream prior to the administration of the radioligand. The most likely explanation for this
phenomenon is the occurrence of click reactions between the radioligand and the TCO-bearing
immunoconjugate in the blood, followed by the localization of the

177

Lu-labeled antibody to the

tumor tissue. Given that we have observed varying degrees of this behavior with different
tetrazine-based radioligands, the binding of the radioligand to plasma proteins — and thus the
extension of its serum half-life — may also play a role. Investigations into this phenomenon are
ongoing in our laboratory.
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24 h

48 h

72 h

Directly

Interval

Interval

Interval

Labeled

Blood

20 ± 5

24 ± 15

17 ± 6

29 ± 23

Heart

67 ± 15

64 ± 28

50 ± 17

77 ± 34

Lung

28 ± 6

27 ± 12

23 ± 6

48 ± 27

Liver

37 ± 7

35 ± 14

30 ± 11

26 ± 14

Spleen

29 ± 10

43 ± 16

38 ± 14

21 ± 20

Stomach

147 ± 34

192 ± 62

150 ± 42

178 ± 68

Small Intestine

141 ± 25

156 ± 70

137 ± 36

94 ± 62

Large Intestine

106 ± 68

86 ± 29

89 ± 34

130 ± 54

Kidney

27 ± 6

19 ± 6

20 ± 5

40 ± 17

Muscle

184 ±30

168 ± 64

153 ± 44

155 ± 67

Bone

82 ± 13

86 ± 32

82 ± 18

71 ± 23

Tumor-to-Organ

Table 3.1 Tumor-to-Organ activity concentration ratios determined from the 120 h biodistribution
time point data of the pretargeted huA33-TCO/[177Lu]Lu-DOTA-PEG7-Tz system, as well as the
directly labeled [177Lu]Lu-CHX-Aʺ-DTPA-huA33 radioimmunoconjugate.
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3.7

Longitudinal Therapy Study
The next step in the investigations was the in vivo validation of the therapeutic efficacy of

the system. To this end, athymic nude mice bearing subcutaneous SW1222 xenografts were
randomly assigned into one of five cohorts (n = 10 each): two control groups and three treatment
groups. The control groups consisted of one cohort in which the mice received huA33-TCO but
not the radioligand and one cohort in which the mice received [177Lu]Lu-DOTA-PEG7-Tz (55.5
MBq, 0.78nmol) but not the immunoconjugate. The three treatment groups each received the same
amount of huA33-TCO (100 µg, 0.6 nmol) and then ⎯ following a 24 h interval ⎯ three different
doses of [177Lu]Lu-DOTA-PEG7-Tz: 18.5 (0.76 nmol), 37.0 (0.79 nmol), or 55.5 (0.78 nmol)
MBq. Tumor volumes were calculated from caliper measurements taken every 3-4 d for the first
three weeks of the study followed by weekly measurements taken until the conclusion of the study
at 70 d (10 half-lives of 177Lu).
As can be seen in Figure 3.3, the treated cohorts exhibited a brief period of tumor growth
followed by drastic and sustained reductions in tumor volume. This very clearly validates the merit
of this pretargeted approach to radioimmunotherapy. In addition, the efficacy of the therapy is
plainly illustrated in the Kaplan-Meier plot of the study. To wit, no mice from the control cohorts
survived past 47 d, while the mice from the experimental groups boasted a perfect survival record
over the course of the study. Critically, a similar dose-dependent therapeutic response was also
observed in a parallel huA33-TCO/[177Lu]Lu-DOTA-PEG7-Tz PRIT study using a 72 h
pretargeting interval and lower activities of the 177Lu-labeled radioligand (Supporting Information;
Figure S3 1).
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Figure 3.3 A longitudinal therapy study of 5 groups of mice (n = 10 each) bearing subcutaneous
SW1222 tumors depicted in (A) normalized tumor volume as a function of time and (B) the
corresponding Kaplan-Meier survival curve. The control groups received either the
immunoconjugate without the radioligand (blue) or the radioligand without the immunoconjugate
(red). The three treatment groups received huA33-TCO (100 µg, 0.6 nmol) followed 24 h later by
either 18.5 (green), 37.0 (purple), or 55.5 (orange) MBq (~0.8 nmol in each case) of [177Lu]LuDOTA-PEG7-Tz. By log-rank (Mantel–Cox) test, survival was significant (p < 0.0001) for all
treatment groups.

3.8

Pretargeted PET Imaging During Longitudinal Therapy Study
During the therapy study, pretargeted PET imaging was performed on representative mice

from each cohort in order to visualize the amount of A33 antigen remaining on the tumor surface
and to probe if additional cycles of huA33-TCO/[177Lu]Lu-DOTA-PEG7-Tz PRIT could be
feasible (Figure 3.4). These imaging protocols were performed on day 27 of the therapy study in
order to ensure that representative mice from every cohort were available for study. To this end,
the mice in question were injected with huA33-TCO (100 µg, 0.6 nmol), and, after a 24 h interval
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period, a

64

Cu-labeled tetrazine radioligand ([64Cu]Cu-SarAr-Tz, 18.5 MBq, 0.95 nmol). PET

images collected 24 h after the administration of the radioligand clearly show uptake of the 64CuSarAr-Tz at the tumor, suggesting that the initial round of PRIT did not saturate the A33 antigen
at the tumor site and that an iterative therapeutic approach is possible. An exploration of this
fractionated approach is ongoing in the laboratory.

Figure 3.4 Pretargeted PET imaging maximum intensity projections of control and treatment mice
obtained on day 27 of the 24 h interval PRIT therapy study. Mice were injected with huA33-TCO
(100 µg, 0.6 nmol) followed 24 h later by injection of [64Cu]Cu-SarAr-Tz (18.5 MBq, 0.7 nmol).
PET images were collected 24 h after the administration of the radioligand.

3.9

Dosimetry Estimations
In order to properly compare the dosimetry of this PRIT approach to conventional RIT, it

was necessary to collect in vivo data with a directly-labeled antibody. To this end, an
immunoconjugate of huA33 bearing the CHX-Aʺ-DTPA chelator —CHX-Aʺ-DTPA-huA33 —
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was synthesized and radiolabeled with 177Lu in high radiochemical purity and specific activity (see
Supplemental Information). Subsequently, biodistribution studies were performed in athymic nude
mice bearing SW1222 human colorectal cancer xenografts. Time activity curves were generated
for both the PRIT and RIT modalities, and the integrals under the curves were determined to
calculate the residence times of 177Lu in each organ. These residence times were next entered into
the OLINDA program to estimate the radiation dose to selected organs as well as the total effective
dose (tissue weighted sum of absorbed doses; Table 3.2).50
The effective dose of the PRIT system was found to be 0.054 mSv/MBq and 0.068
mSv/MBq for the RIT approach. This reduction is admittedly not as dramatic as we had hoped and
had observed previously in our pretargeted PET imaging studies.35 In the latter, however, the
adoption of a pretargeted approach facilitates the use of short-lived radionuclides that would
normally be incompatible with antibody-based vectors, such as 64Cu (t1/2 = 12.7 h), 18F (t1/2 = 107
min), and
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Ga (t1/2 = 68 min). In this case, however, we do not have that option, as effective

therapeutic radionuclides with short half-lives are few and far between. It is important to note,
however, that the red marrow is typically the dose limiting organ for RIT, with a maximum
tolerated dose of 150 cGy.56 As can be seen in our dosimetry estimates, the dose received by the
red marrow during PRIT is nearly half of that produced by RIT: 0.059 mGy/MBq compared to
0.105 mGy/MBq. Consequently, the dose reductions observed in PRIT could enable the
administration of larger initial doses to the patient without marrow-related toxicities.
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Pretargeting with
177

Organ/Tissue
Adrenals
Brain
Breasts
Gallbladder Wall
LLI Wall
Small Intestine
Stomach Wall
ULI Wall
Heart Wall
Kidneys
Liver
Lungs
Muscle
Ovaries
Pancreas
Red Marrow
Osteogenic Cells
Skin
Spleen
Testes
Thymus
Thyroid
Urinary Bladder Wall
Uterus
Total Body
Effective Dose
(mSv/MBq)

huA33-TCO and LuDOTA-PEG7 -Tz
(24 h interval)
Absorbed Dose
(mGy/MBq)
0.056
0.055
0.053
0.06
0.059
0.066
0.057
0.058
0.065
0.055
0.039
0.043
0.036
0.057
0.056
0.059
0.292
0.052
0.035
0.054
0.055
0.055
0.056
0.057
0.070
0.054

177

Lu-CHX-A˝-DTPAhuA33
Absorbed Dose
(mGy/MBq)
0.034
0.029
0.028
0.035
0.041
0.082
0.048
0.038
0.076
0.168
0.156
0.126
0.129
0.034
0.035
0.105
0.651
0.028
0.131
0.030
0.032
0.032
0.033
0.034
0.097
0.068

Table 3.2 Radiation dose estimates for a 70-kg adult male based on biodistribution data for the
huA33-TCO/ [177Lu]Lu-DOTA-PEG7-Tz PRIT system with a 24 h interval (left) and the directlylabeled [177Lu]Lu-CHX-A˝-DTPA-huA33 radioimmunoconjugate (right).
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3.10 Conclusion
In the preceding pages, we have described the successful demonstration of PRIT of mice
bearing human colorectal carcinoma tumors using a strategy based on the in vivo ligation of
[177Lu]Lu-DOTA-PEG7-Tz and huA33-TCO. A pronounced dose-dependent therapeutic effect
was observed. Moreover, the data reveal modest dosimetric improvements over traditional RIT
with a directly-labeled radioimmunoconjugate. Looking forward we believe that implementation
of a Tz-bearing clearing agent to bind to any residual antibody in circulation at the time of
radioligand administration will help to improve dosimetry. However, this will make the
pretargeting strategy more cumbersome, requiring three injections as well as requiring approval
for an additional agent before any clinical studies can occur. Future investigations will focus
primarily on enhancing the dosimetric benefits of PRIT through the use of Tz-bearing clearing
agents, fractionated dosing schedules, and shorter-lived therapeutic radionuclides such as

211

At.

Ultimately, we believe these data suggest that this Tz/TCO-based approach to PRIT can be
translated to other tumor types with success.
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3.11 Supporting Information

Table S3 1 Full biodistribution data of nude mice bearing SW1222 xenografts. Top three panels
state the biodistribution values of huA33-TCO/[177Lu]Lu-DOTA-PEG7-Tz pretargeting with
intervals of 24, 48, and 72 hours. The final section displays the activity concentration values for
the directly labeled [177Lu]Lu-CHX-Aʺ-DTPA-huA33 radioimmunoconjugate.
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Figure S3 1 A longitudinal therapy study of 5 groups of mice bearing subcutaneous SW1222
tumors depicted in (A) normalized tumor volume as a function of time and (B) the corresponding
Kaplan-Meier survival curve. The control groups received with the immunoconjugate without the
radioligand (blue) or the radioligand without the immunoconjugate (red). The three treatment
groups received huA33-TCO (100 µg, 0.6 nmol) followed 72 h later by either 7.4 (green), 16.7
(purple), or 33.3 (orange) MBq of [177Lu]Lu-DOTA-PEG7-Tz. By log-rank (Mantel–Cox) test,
survival was significant (P < 0.01) for the PRIT group receiving 33.3MBq. Median survival was
determined to be 21 days for the huA33-TCO only control group, 15 days for the radioligand only
control group, and 35.5, 41, and 67 days for those subjects receiving 7.4, 16.7, or 33.3 MBq
respectively.

3.11.1 Preparation of [177Lu]Lu-DOTA-PEG7-Tz:
[177Lu]Lu-DOTA-PEG7-Tz was prepared as previously described

37

. [177Lu]LuCl3 was

obtained from the research reactor at The University of Missouri where it is produced from Lu176 targets with a final specific activity of ≤ 25 Ci/mg. A solution of DOTA-PEG7-Tz (5 - 25 µg;
4.1 - 20.7 nmol) in NH4OAc buffer (0.25 M, pH 5.5, 200 µL) was first prepared. Then, the desired
amount of [177Lu]LuCl3 in 0.1M HCl (1500 - 7500 µCi, 55.5 - 277.5 MBq) was added to the
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reaction mixture, and the solution was placed on an agitating thermomixer at 300 rpm for 10 min
at 37 °C. After this incubation, the progress of the [177Lu]Lu-DOTA-PEG7-Tz radiolabeling was
determined by iTLC which revealed quantitative labeling of >98% radionuclidic purity, thus no
further purification was deemed necessary. The final molar activity of [177Lu]Lu-DOTA-PEG7-Tz
was 17.2 ± 5.7 GBq/µmol; n = 4.

3.11.2 Preparation of [177Lu]Lu-CHX-Aʺ-DTPA-huA33
An aliquot of prepared huA33-CHX-Aʺ-DTPA (0.3 mg, 2.0 nmol) was buffer exchanged
to be suspended in chelexed 0.25 M NH4OAc with 34 mM ascorbic acid (pH 5.5) using centrifugal
filtration units with a 30,000 Da molecular weight cut off (AmiconTM Ultra 0.5mL, Millipore
Corp., Billerica, MA). To this solution 2.7 mCi (100 MBq) of [177Lu]LuCl3 was added and
incubated for 1 hour at 37 °C with shaking at 400 rpm. [177Lu]LuCl3 was obtained from the
research reactor at The University of Missouri where it is produced from Lu-176 targets with a
final specific activity of ≤ 25 Ci/mg. The radiolabeled immunoconjugate was the purified using
size-exclusion chromatography (Sephadex G-25M, PD-10 column, GE Healthcare; dead volume
= 2.5 mL, eluted with 2 mL fractions of PBS with 34 mM ascorbic acid, pH 7.4) with an overall
radiochemical yield of 82.0%, radiochemical purity of 99.6 % as determined by iTLC, with a molar
activity of 31.6 GBq/µmol; n = 1.

3.11.3 Preparation of [64Cu]Cu-SarAr-Tz
[64Cu]Cu-SarAr-Tz was prepared as previously described.35 A solution of Tz-SarAr (5 - 25
µg; 6.9 - 34.9 nmol) in NH4OAc buffer (0.2 M, pH 5.5, 200 µL) was first prepared. Then, the
desired amount of [64Cu]CuCl2 in 0.1 M HCl (3000 µCi; 111 MBq) was added to the reaction
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mixture, and the solution was placed on an agitating thermomixer at 300 rpm for 30 minutes at 25
°C. After this incubation, the [64Cu]Cu-SarAr-Tz was purified via reverse phase C18 HPLC (tR =
8.7 min) to yield the completed radioligand in >99% radionuclidic purity, and a molar activity of
19.4 ± 1.5 GBq/µmol; n = 4.

3.11.4 Determination of the TCO occupancy of huA33-TCO
The TCO occupancy of huA33-TCO was determined as previously described

35, 37

. A

solution of huA33-TCO (100 µg; 0.66 nmol) in 900 µL PBS (pH 7.4) was first prepared (0.74
µM). Next, 100 µL of a 1 mM solution of Tz-PEG7-AF680 in DMSO was added to create a reaction
volume of 1000 µL and concentrations of 0.66 µM A33-TCO and 100 µM Tz-PEG7-AF680 (a
~150-fold excess of Tz). This solution was placed on an agitating thermomixer at 300 rpm at 25
°C. After 180 minutes of incubation, the resulting fluorophore-labeled immunoconjugate was
purified using size-exclusion chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare;
dead volume = 2.5 mL, eluted with 2 mL of PBS, pH 7.4) and concentrated by using centrifugal
filtration units with a 50,000 Da molecular weight cut off (AmiconTM Ultra 4, Millipore Corp.,
Billerica, MA). The degree of labeling (DOL) was determined by UV-Vis analysis. Absorbance
measurements were taken at 280 nm and 680 nm, and the DOL was calculated using the following
formulas:
AmAb = A280 – Amax(CF)
DOL = [Amax*MWmAb]/[[mAb]*εAF680]
where the correction factor (CF) for AF680 was given as 0.05 by the supplier, MWhuA33 = 150,000,
εAF680 = 184,000, and ε280, huA33-TCO = 225,000. Given the rapid and quantitative nature of the
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IEDDA reaction, the degree of labeling of AF680 was assumed to be the degree of labeling of
TCO.

3.11.5 Cell culture
Human colorectal cell line SW1222 was obtained from the Ludwig Institute of Cancer
Research and maintained in Minimum Essential Medium, supplemented with 10% heatinactivated fetal calf serum, 2 mM glutamine, 100 units/mL penicillin, and 100 units/mL
streptomycin in a 37 °C environment 7 containing 5% CO2. Cell lines were harvested and passaged
every 8-10 days using 0.25% trypsin/0.53 mM EDTA in Hank’s Buffered Salt Solution without
calcium and magnesium. All media was purchased from the Media Preparation Facility at
Memorial Sloan Kettering Cancer Center.

3.11.6 Subcutaneous Xenograft Models
Female athymic homozygous nude mice, strain Crl:NU(NCr)-Foxn1nu (Charles River
Laboratories, Wilmington, MA) age between 6-8 weeks were xenografted subcutaneously with
5x106 SW1222 cells, suspended in 150 µL of a solution containing a 1:1 mixture of Matrigel
(Becton Dickinson, Bedford, MA) and cell culture medium. SW1222 tumors were grown for 1418 days post-implantation prior to imaging or biodistribution.

3.11.7 PET imaging
One subject from each cohort was administered huA33-TCO (100 µg, 0.6 nmol in 200 µL
sterile PBS) via intravenous tail vein injection. After an accumulation interval of 24 h, the same
mice were then administered [64Cu]Cu-SarAr-Tz (500 µCi; 18.5MBq in 200 µL sterile PBS), also
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via intravenous tail vein injection (t = 0). The molar activity of the radiotracer was adjusted using
SarAr-Tz such that the molar ratio of Tz injected: huA33 injected ≈ 1:1. Static scans were recorded
at 24 h after injection of the radioactivity for a total scan time of 15 minutes per scan. An energy
window of 350-700 keV and a coincidence timing window of 6 ns were used. Data were sorted
into 2-dimensional histograms by Fourier rebinning, and transverse images were reconstructed by
filtered back-projection (FBP) into a 128 × 128 × 63 (0.72 × 0.72 × 1.3 mm) matrix. The imaging
data was then normalized to correct for non-uniformity of response of the PET, dead-time count
losses, positron branching ratio, and physical decay of the isotope to the time of injection- but no
attenuation, scatter, or partial-volume averaging correction was applied. Activity concentrations
(percentage of dose per gram of tissue [%ID/g]) were determined by conversion of the counting
rates from the reconstructed (filtered back-projection) images. Maximum intensity projection
(MIP) images were generated from 3-dimensional ordered subset expectation maximization
reconstruction (3DOSEM). All of the resulting images were analyzed using ASIPro VM™
software.

3.11.8 Pretargeted Biodistributions
The acute biodistribution of [177Lu]Lu-DOTA-PEG7-Tz was determined using a SW1222
subcutaneous xenograft (right flank, ~200mm3) model in athymic, nude mice. Mice were
randomized into groups and warmed gently using a heat lamp prior to being injected with 100 µg
(0.6 nmol) of huA33-TCO via intravenous tail vein injection. After an accumulation interval period
of 24 h, the same mice were then administered [177Lu]Lu-DOTA-PEG7-Tz (300-350 µCi; 11.113.0 MBq, 0.6-0.7 nmol, in 200 µL sterile PBS) also via intravenous tail vein injection. At the
appropriate time post injection of radioactivity, mice (n = 4) were euthanized via asphyxiation
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using CO2(g) and 13 tissues including the tumor were collected, dried in open air for 5 minutes,
and placed into pre-weighed tubes. The mass of each organ was determined and then each sample
was counted using a Wizard2 automatic gamma counter calibrated for 177Lu. A calibration curve
generated from standards of known activity was used to convert counts into activity. The counts
from each sample were decay- and background corrected from the time of injection, and the
activity in each sample was then converted to %ID/g by normalization to the total activity injected
into the respective animal.

3.11.9 Directly labeled biodistribution
The acute biodistribution of prepared [177Lu]Lu-CHX-Aʺ-DTPA-huA33 was determined
using a SW1222 subcutaneous xenograft (right flank, ~200 mm3) model in athymic, nude mice.
Mice were randomized into groups and warmed gently using a heat lamp prior to being injected
with 5 µg of [177Lu]Lu-CHX-Aʺ-DTPA-huA33 (S.A. 5.7 µCi/µg) in PBS with 34 mM ascorbic
acid (pH 7.4) via intravenous tail vein injection. At the appropriate time post injection, mice (n =
4) were euthanized via asphyxiation using CO2(g) and 13 tissues including the tumor were
collected, dried in open air for 5 minutes, and placed into pre-weighed tubes. The mass of each
organ was determined and then each sample was counted using a Wizard2 automatic gamma
counter calibrated for 177Lu. A calibration curve generated from standards of known activity was
used to convert counts into activity. The counts from each sample were decay- and background
corrected from the time of injection, and the activity in each sample was then converted to %ID/g
by normalization to the total activity injected into the respective animal.
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3.11.10 Dosimetry
The biodistribution data for the [177Lu]Lu-DOTA-PEG7-Tz / huA33-TCO pretargeting
system described in this investigation as well as the directly-labeled [177Lu]Lu-CHX-Aʺ-DTPAhuA33 was expressed as normal-organ mean standard uptake values (SUVs) versus time postadministration. Assuming, in first order, that SUVs are independent of body mass and thus the
same among species, the mean SUV in mouse organ i, SUVi, was converted to the fraction of the
injected dose in each human organ I, FIDI, using the following formula:
MassofHumanOrgan I
FIDI = SUVi • MassofHumanTotalBody

These data were decay corrected and fit to exponential time-activity functions. The residence time
€

in a human organ i (ti, in µCi-h/µCi) was calculated by integrating the time-activity function in
organ i, replacing the biological clearance constant, (lb)x for each component, x, of the fitted
exponential function with the corresponding effective clearance constant, (le)x [(le)x = (lb)x + lp,
where lp is the physical decay constant of the radionuclide. The resulting organ residence times
were entered into the OLINDA computer program utilizing the 70-kg Standard Man anatomic
model to yield the mean organ absorbed doses and effective dose in rad/mCi and rem/mCi,
respectively, which were then converted to cGy/MBq.50

3.11.11 Longitudinal therapy study
Mice bearing established SW1222 subcutaneous tumors (mean tumor volume 250 ± 50
mm3) were randomly sorted into 5 groups of 10 mice per group. In order to see the therapeutic
window of the pretargeted methodology, the treatment groups received injections of the
radioligand loaded with 500, 1000, or 1500 µCi (18.5, 37.0, 55.5 MBq) via the lateral tail vein 24
h after administration of huA33-TCO (100 µg in 200 µL of 0.9% saline). The remaining two
50

cohorts served as control groups, receiving either huA33-TCO alone (100 µg in 200 µL of 0.9%
saline) or 1500 µCi (55.5 MBq) of [177Lu]Lu-DOTA-PEG7-Tz with no administered huA33-TCO.
All mice were weighed, and the tumor burden was assessed by caliper measurement every 3-4
days until day 21, and then every 7 days thereafter until the conclusion of the experiment. Tumor
volume was calculated using the formula for volume of an ellipsoid. Mice were sacrificed if the
tumor grew to >1.0 cm3 or if the mouse lost >20% of its body mass during the course of the study.

3.11.12 Statistical Analysis
Biodistribution data were analyzed by the unpaired, two-tailed Student’s t-test. Differences
at the 95% confidence level (P < 0.05) were considered to be statistically significant. For the
therapy study, Kaplan–Meier survival analysis was performed with Prism software (version 7.0;
GraphPad Software). Differences at the 95% confidence level (P < 0.05) were considered to be
statistically significant.
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Chapter 4:
4.1

Optimization of Dosimetry Through the Use of Clearing Agents

Introduction
In the previous chapter we presented results comparing a pretargeted therapy approach to

a traditional, directly labeled radioimmunoconjugate.51 The overall radiation dose estimates were
lowered using the pretargeted strategy, however this reduction was not as drastic as we anticipated,
especially compared to the 30-fold reduction we have observed with our counterpart PET imaging
systems.35, 57 In response to this shortcoming, recent work in our lab has gone into developing
methods to improve the dosimetric benefits of pretargeting. One potential strategy that has
emerged is the use of clearing or masking agents.36, 58, 59 The purpose of these clearing agents is to
clear or inactivate any residual antibody remaining in circulation at the time of radioligand
administration, effectively serving to reduce background organ radioactivity concentration levels.
While it could be suggested that the pretargeting interval simply be extended to allow for
complete clearance of antibody, this process can take weeks. Stability of the immunoconjugate,
and the TCO in particular, is limited and the use of a clearing or masking agent could be warranted.
Collaborators at MSKCC and Tagworks Pharmaceuticals have developed two clearing agents that
fundamentally work in the same manner (Figure 4.1).36, 59 Both have been functionalized to bear
tetrazine groups on its surface to inactive the residual mAb-TCO in circulation. The large size of
the foundation, either albumin or dextran, theoretically guarantees that no extravasation of the
molecule from the vasculature will occur, preserving the reactivity of tumor-bound TCOs.
Pretargeting with the inclusion of a masking agent proceeds via 3 steps: 1) a TCOfunctionalized antibody is introduced intravenously and allowed time to accumulate and clear from
circulation; 2) the tetrazine-functionalized masking agent inactivates any residual circulating
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mAb-TCO by “clicking” to their TCO groups; 3) the tetrazine bearing radioligand is administered
and binds to any TCO-mAb at the tumor and quickly clears from background tissue.
Indeed, the introduction of yet another component to the already complex PRIT scheme
can create new complications, particularly in the context of logistics and regulatory approval.
Ultimately, however, we are hopeful and cautiously optimistic that the optimization of this
approach to PRIT will lead to the creation of a safe and effective approach to the targeted
radiotherapy of patients in the clinic.
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Figure 4.1 Clearing agents used in these experiments. A) schematic representation of galactosealbumin-tetrazine, Tz-Alb; adapted from: Rossin, R.; et. al.; Diels-alder reaction for tumor
pretargeting: In vivo chemistry can boost tumor radiation dose compared with directly labeled
antibody. Journal of Nuclear Medicine 2013, 54, 1989-1995 © SNMMI.36 B) Dextran-tetrazine,
Tz-DP; adapted from Meyer, J.-P.; et. al.; Bioorthogonal masking of circulating antibody–tco
groups using tetrazine-functionalized dextran polymers. Bioconjugate Chemistry 2018, 29, (2),
538-545. Copyright 2018 American Chemical Society.59
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4.2

Synthesis of Dextran-Tetrazine masking agent; Tz-DP
Synthesis of dextran-tetrazine constructs was conducted by collaborators at MSKCC and

synthesized as previously described.59 Briefly, amino-dextran polymers (MW ~ 2 MDa) were
dissolved in phosphate-buffered saline (pH 7.4) and the pH was increased to 8.5 - 9 using 0.1 M
Na2CO3. Tz-NHS ester was dissolved in dimethylformamide and added slowly to the aminodextran solution, and the reaction was agitated at room temperature and 700 rpm for 2 h. The
dextran-tetrazine construct was purified into PBS via PD-10 size-exclusion columns, and the
tetrazine concentration was calculated using UV/Vis spectroscopy. Tz/DP ratios depend upon the
equivalents of Tz-NHS used and can range from 62-654 Tz/DP. DP-Tz aliquots were stored at 80°C.

4.3

Synthesis of Galactose-Albumin-Tetrazine Clearing Agent; Tz-Alb
Synthesis of galactose-albumin-tetrazine constructs was conducted by collaborators at

Tagwork Pharmaceuticals and synthesized as previously described.36 Briefly, galactose
conjugation to mouse serum albumin (MSA) was performed with a reactive imino-derivative
directly coupled to MSA via the terminal amino-groups of its Lys residues. The galactosefunctionalized albumin was then modified with tetrazine moieties via its lysine residues and TzNHS. The tetrazine modification grade was determined by MALDI-TOF analysis. GalactoseMSA-tetrazine: [M+H+] = 79010 m/z, which corresponds to a mean of 9.7 tetrazines per galactoseMSA.

55

4.4

Biodistribution Studies
Initial biodistributions were conducted in athymic nude mice bearing subcutaneous

SW1222 xenografts. Mice were randomized into groups and warmed gently using a heat lamp to
cause swelling of the lateral tail vein prior to being administered huA33-TCO (100 µg, 0.6 nmol
in 150 µL of 0.9% saline) 24 hours before radioligand injection. A 24-hour antibody accumulation
interval was maintained from our previous time-optimization studies (Chapter 3). The clearing
agent dose was administered according to our collaborators’ recommendation: 160 µg (20 nmol
Tz) of Tz-Alb in saline was injected 2 hours prior to radioligand administration or 55 nmol of TzDP, 30 minutes prior to [177Lu]Lu-Tz-PEG7-DOTA (300 µCi; 11.1 MBq, 0.7 nmol) injection.
Organs were harvested at designated time points post administration of radioligand (n = 4).
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Figure 4.2 Biodistribution of in vivo pretargeting with huA33-TCO and [177Lu]Lu-DOTA-PEG7Tz in athymic nude mice bearing subcutaneous SW1222 human colorectal cancer tumors using a
pretargeting interval of 24 hours and a 2 hour preinjection of 20 nmol of Tz-Alb (n=4 per time
point).
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Table 4.1 Radiation dose estimates for a mouse model as well as a 70-kg adult male based on
biodistribution data for a directly labeled radioimmunoconjugate [177Lu]Lu-CHX-A˝-DTPAhuA33(left), the huA33-TCO/[ 177Lu]Lu-DOTA-PEG7-Tz PRIT system with a 24 h interval without
CA (middle) and with a 2 hour preinjection of 20 nmol of Tz-Alb. (right).
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Figure 4.3 Biodistribution of in vivo pretargeting with huA33-TCO and[177Lu]Lu-DOTA-PEG7Tz in athymic nude mice bearing subcutaneous SW1222 human colorectal cancer tumors using a
pretargeting interval of 24 hours and a 30 min preinjection of 55 nmol of Tz-DP (n=4 per time
point).
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Table 4.2 Radiation dose estimates for a mouse model as well as a 70-kg adult male based on
biodistribution data for a directly labeled radioimmunoconjugate [177Lu]Lu-CHX-A˝-DTPAhuA33(left), the huA33-TCO/[ 177Lu]Lu-DOTA-PEG7-Tz PRIT system with a 24 h interval without
CA (middle) and with a 30 min preinjection of 55 nmol of Tz-DP. (right).
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Utilizing our antibody-antigen system, we observe similar results with both Tz-Alb and
Tz-DP clearing agents. As hoped, uptake in the blood and blood-perfused organs is substantially
lowered at 24 h (0.63 ± 0.2 and 0.31 ± 0.05 %ID/g using Tz-Alb or Tz-DP, respectively) when
compared to mice that did not receive a clearing agent (3.7 ± 0.62 %ID/g). Unfortunately, this
decrease coincided with a reduction in tumor uptake as well, with both groups treated with clearing
agent dropping to ~5 %ID/g compared to 21 ± 2.9 %ID/g for clearing agent free mice (Figure 3.2).
Between the two masking agents, Tz-DP displayed higher retention at the tumor site as
well as lower residence in the blood (Figure 4.3). These findings translate to a higher tumor: blood
therapeutic index (ratio of absorbed dose) which is indeed quite favorable for image contrast if
using a positron or gamma emitting nuclide. Noticeably, uptake in all other organs is lower when
using the Tz-Alb CA over Tz-DP (Figure 4.2). This also translates to higher therapeutic indices of
tumor: background organs as well as a slightly lower effective dose. However, the retention in the
blood is higher which leads to lower tumor-blood ratios than when using Tz-DP.
While the improvements to background organ absorbed dose is quite promising, the
therapeutic potential of this system is still subpar. When comparing the tumor dose delivered using
a clearing agent, it is about one-fifth the dose delivered in a pretargeting system with no CA and
one-tenth the dose delivered in directly labeled antibody RIT. To be a realistic candidate for
clinical translation, the uptake at the tumor must be as high as possible to deliver a dose of 10,000
cGy to the tumor, while also decreasing the dose to healthy background tissue.5 The next step was
therefore to explore pretargeting parameters related to administration of the CA in the hopes of
optimizing the therapeutic indices.
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4.5

Clearing Agent Circulation Time Optimization Studies
We conducted single time-point biodistributions to investigate the role of CA circulation

time on effective masking of residual circulating antibody-TCO in the bloodstream. To this end,
athymic nude mice bearing subcutaneous SW1222 xenografts were administered huA33-TCO 24
hours prior to radioligand administration. Mice then received 160 µg (20 nmol Tz) of Tz-Alb in
saline 30 min, 1, 2 or 3 hours prior to radioligand administration (n = 4 per cohort) or 55 nmol of
Tz-DP 30 min, 1 h, or 2 h prior to injection of [64Cu]Cu-SarAr-Tz (500µCi; 18.5 MBq, 0.7nmol).
The control cohort received the same dose of antibody-TCO and radioligand, but received no dose
of clearing agent. The change of radioisotope from 177Lu to 64Cu was made in order to permit PET
imaging in conjunction with biodistributions. As such, imaging was performed 4 and 24 hours post
administration of radioligand and following the final time point the biodistribution was performed.
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Figure 4.4 PET imaging of athymic nude mice bearing SW1222 right shoulder xenografts taken 4
and 24 hours after administration of [64Cu]Cu-SarAr-Tz. Mice received huA33-TCO (100 µg,
0.6nmol) 24 hours prior to radioligand and 55nmol Tz-DP either 0.5, 1, or 2 hours prior to
radioligand. Images are maximum intensity projections.
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Figure 4.5 Biodistribution of athymic nude mice bearing SW1222 right shoulder xenografts 24
hours after administration of [64Cu]Cu-SarAr-Tz. Mice received huA33-TCO (100 µg, 0.6nmol)
24 hours prior to radioligand and either 55nmol Tz-DP 0.5, 1, or 2 hours prior to radioligand or
20 nmol of Tz-Alb 0.5, 1, 2, or 3 hours prior to [64Cu]Cu-SarAr-Tz (n = 4 per cohort).
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Figure 4.6 Tumor-to-tissue ratios of activity concentration based on biodistribution results of
athymic nude mice bearing SW1222 right shoulder xenografts 24 hours after administration
of[64Cu]Cu-SarAr-Tz. Mice received huA33-TCO (100 µg, 0.6 nmol) 24 hours prior to radioligand
and either 55nmol Tz-DP 0.5, 1, or 2 hours prior to radioligand or 20 nmol of Tz-Alb 0.5, 1, 2, or
3 hours prior to [64Cu]Cu-SarAr-Tz (n = 4 per cohort).

A reduction in tumor and blood uptake is observed with all preinjection intervals attempted
which afforded enhanced image contrast as early as 4 hours post 64Cu administration (Figure 4.4)
However, we can see that background organ uptake is quite comparable to the control cohort,
which typically signifies that there will be minimal improvement to the dosimetry of the healthy
background tissue (Figure 4.5). Looking at the tumor-to-tissue ratios (Figure 4.6) we can see
modest improvement to blood and kidney, but all other ratios are maintained or slightly decreased.
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4.6

Antibody Localization Time Study: 72 hour preinjection
With these findings in mind, we next investigated the role of antibody localization time,

increasing it from 24 to 72 hours in hopes of driving tumor uptake by increasing the amount of
antibody bound at the tumor site. HuA33-TCO (100 µg, 0.6nmol) was injected into the tail-vein
of SW1222 xenograft bearing mice 72 hours prior to radioligand administration. Clearing agent,
Tz-DP or Tz-Alb, was injected either 0.5 or 2 hours prior to injection of [64Cu]Cu-SarAr-Tz (500
µCi, 0.7 nmol). PET imaging was performed 4 hours and 24 hours post injection of radioligand
and organs were harvested after the final imaging timepoint (n = 3 per cohort).

Figure 4.7 PET imaging of athymic nude mice bearing SW1222 right shoulder xenografts taken 4
and 24 hours after administration of [64Cu]Cu-SarAr-Tz. Mice received huA33-TCO (100 µg,
0.6nmol) 72 hours prior to radioligand and either 55 nmol Tz-DP or 20 nmol of Tz-Alb either 0.5,
or 2 hours prior to radioligand (n = 3 per cohort). Images are maximum intensity projections.
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Figure 4.8 Biodistribution of athymic nude mice bearing SW1222 right shoulder xenografts 24
hours after administration of [64Cu]Cu-SarAr-Tz. Mice received huA33-TCO (100 µg, 0.6 nmol)
72 hours prior to radioligand and either 55 nmol Tz-DP or 20 nmol of Tz-Alb either 0.5, or 2 hours
prior to radioligand (n = 3 per cohort).

At first glance we can see that the 72-hour antibody localization time did not support our
idea of driving tumor uptake by allowing more time for antibody to bind at the tumor site. Using
a 72-hour antibody localization time, the same conditions that reached 5.7 ± 0.9 %ID/g with a 24hour antibody localization time (20 nmol Tz-Alb injected 0.5 hours prior to radioligand), only
reached 3.3 ± 1.7 %ID/g (Figure 4.8). We do however see a significant decrease in blood uptake
when a clearing agent is used. We can see from Figure 4.9 that the tumor-to-blood and tumor-to67

intestine ratio for the Tz-DP cohorts is improved over the non-clearing agent cohort. These
promising results may yield improved dosimetry for the pretargeting strategy not observed when
using a 24 hour preinjection interval. To investigate the dosimetric burden, a longitudinal
biodistribution was conducted using the highest performing conditions: 55 nmol Tz-DP
administered 30 min prior to radioligand injection.

Figure 4.9 Tumor-to-tissue ratios of activity concentration based on biodistribution results of
athymic nude mice bearing SW1222 right shoulder xenografts 24 hours after administration of
[64Cu]Cu-SarAr-Tz. Mice received huA33-TCO (100 µg, 0.6nmol) 72 hours prior to radioligand
and either 55 nmol Tz-DP or 20 nmol of Tz-Alb either 0.5, or 2 hours prior to radioligand (n=3
per cohort).
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4.7

Longitudinal Biodistribution using 177Lu to Calculate Dosimetry
A full longitudinal biodistribution was conducted in order to calculate radiation absorbed

doses when the Tz-DP masking agent is used with a 72 hour preinjection interval. Athymic nude
mice bearing SW1222 subcutaneous xenografts on their right shoulder were administered 100 µg,
0.6 nmol of huA33-TCO via lateral tail-vein 72 hours prior to radioligand administration. Clearing
agent, Tz-DP (55 nmol), was injected 0.5 hours prior to injection [177Lu]Lu-Tz-PEG7-DOTA (300
µCi, 0.7 nmol). Organs were harvested at 4, 24, 48, and 120 hours post-administration of
radioligand (n = 5 per time point).

Figure 4.10 Biodistribution data for the huA33-TCO (100 µg, 0.6nmol) and [

177

Lu]Lu-DOTA-

PEG7-Tz (11.1 MBq, 0.7 nmol) pretargeting system with a 72 h interval without CA (gray) and
with a 30 min preinjection of 55 nmol of Tz-DP (purple).
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Tumor uptake is comparable to the 24 h preinjection study (Figure 4.3), with a maximum
tumor uptake of 3.6 ± 0.4 %ID/g, though blood uptake remained substantially low. It is interesting
to note here that in masking agent-free mice, the amount of activity in the tumor rises substantially
over the time course of the study from 3.3 ± 1.2 %ID/g at 4 h to 12.7 ± 2.3 %ID/g at 120 h (Figure
4.10). Mice administered masking agent, however, do not see this increase. This leads us to
conclude that click ligations between radioligand and antibody circulating in the blood then finding
its way to the tumor plays a larger part in traditional pretargeting than previously thought. The
dosimetry values for a mouse model and the extrapolation to a 70 kg male are shown in Table 4.3.
We see once again that the therapeutic index of tumor-to-blood is increased with implementation
of a clearing agent. However, ratios to all other organs are decreased which ultimately results in
only modest improvement to the dosimetry.
We can see that the answer to improving dosimetry for therapy does not solely lie in
clearing residual antibody from circulation. In vivo click ligations at the tumor site must be
increased in order to increase localized radioactivity at the tumor site. There are two potential
avenues to explore for these efforts; 1) increase the number of TCO groups on the antibody
construct, or 2) increase the amount of antibody localized at the tumor site.
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Table 4.3 Radiation dose estimates for a mouse model as well as a 70-kg adult male based on
biodistribution data for the huA33-TCO/ 177Lu-DOTA-PEG7-Tz PRIT system with a 72 h interval
without CA (left) and with a 30 min preinjection of 55 nmol of Tz-DP (right).
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4.8

Conclusion
We have successfully demonstrated that utilizing a clearing agent is an effective way to

increase tumor-to-blood therapeutic index while modestly decreasing radiation absorbed dose. The
drastic reduction in activity concentration in the blood and background organs in line with the
purpose of a clearing agent: clearing activity from accumulating in non-target tissue. These effects
can be applied to great extent for pretargeted molecular imaging applications as contrast is indeed
improved with use of a clearing agent. However, for therapeutic applications absolute tumor
absorbed dose is decreased when compared to traditional pretargeting. This leads to the conclusion
that decreasing residual antibody-TCO in circulation is not sufficient as a solution to dosimetric
hurdles. We also found that significant amount of tumor uptake in pretargeting approaches is
driven by circulating antibody clicking with radioligand in the blood and then binding to the tumor
over time. Use of a masking agent serves to eliminate this route of binding and so tumor uptake
is substantially lower. It is therefore imperative to find ways of increasing tumor accumulation in
order to further enhance the efficacy and clinical potential of pretargeted radioimmunotherapy.
One potential strategy will be discussed in the following chapter.
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Chapter 5:
5.1

Optimization of Dosimetry Through the Use of a Dendritic Antibody

Introduction
In a pretargeting approach based on the IEDDA reaction, radiotracer accumulation at the

tumor site is a function of the number of Tz-TCO click ligations. Undoubtedly, a number of factors
can affect uptake of the radioligand; for example, previous work has shown that trans-cyclooctene
can isomerize in vivo to the unreactive cis-cyclooctene, preventing the tetrazine ligation from
occurring.30, 60 Increasing the number of TCOs on each antibody can therefore improve the odds
that one will still be reactive when it encounters a tetrazine. With a greater probability of more
reactive TCOs for ligation, tumor uptake will have the opportunity to reach its maximum potential.
Recent work in our lab has gone into developing a dendrimer scaffold for site specific
conjugation of TCO moieties to the heavy chain glycans of the huA33 antibody (sshuA33-DENTCO).61 This modular, facile conjugation route allows for incorporation of 8 TCO groups per
antibody without affecting immunoreactivity. Results from pretargeted PET imaging studies show
that the sshuA33-DEN-TCO immunoconjugate can double tumor uptake in as little as 4 hours postinjection of radioligand. In this chapter we combine the use of sshuA33-DEN-TCO with our
radioligand for therapeutic applications [177Lu]Lu-DOTA-PEG7-Tz, perform biodistribution
studies and calculate radiation dosimetry to evaluate if the sshuA33-DEN-TCO immonoconjugate
is a contender for PRIT applications.

5.2

Synthesis of DBCO-DEN-TCO
The synthesis of the TCO-bearing dendrimer bifunctional ligand was performed as

previously described.61 In short, the commercially available G1 PAMAM dendrimer was first
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reduced with tris(2-carboxyethyl)phosphine (TCEP) for 1 h at 25 °C to cleave the disulfide core.
Next, DBCO-PEG4-maleimide was added in molar excess and the reaction mixture and
incubated at 25 °C for 24 h to produce the amine terminated G0.5-PAMAM-PEG4-DBCO. The
final step was the addition of TCO-NHS in basic sodium carbonate buffer. G0.5-PAMAM-PEG4DBCO was incubated with 80 molar equivalents of TCO-NHS and allowed to react for 48 h at
25 °C. After chromatographic purification, the final product DBCO-DEN-TCO was collected in
33% yield. Characterization by high resolution mass spectrometry revealed that the maleimide
linkage underwent hydrolysis; however, it has been demonstrated in literature that this affects
neither the linkage nor the utility of the molecule.62

5.3

Synthesis of sshuA33-DEN-TCO
The site specific conjugation of the

ss

huA33-DEN-TCO was performed as previously

described (Figure 5.2).61 Briefly, huA33 was treated with EndoS and then GalT(Y289L)/GalNAz
to first cleave the heavy chain glycans and then cap them with an azide modified galactose residue,
producing sshuA33-N3. DBCO-DEN-TCO was then attached to the immunoconjugate sshuA33-N3
by overnight incubation in aqueous buffer at 25°C. The final product ⎯ sshuA33-DEN-TCO ⎯
was purified via size exclusion chromatography and characterized by MALDI-ToF to confirm the
presence of 2.0 DBCO-DEN-TCO ligands per antibody. This translates to 8.0 TCO groups per
ss

huA33-DEN-TCO construct.
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Figure 5.1 Synthesis of the DBCO-DEN-TCO ligand. This scheme was originally published in
Cook, B.E. et al. Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations,
Bioconjugate Chemistry, 2018, 29, (8), pp 2734–2740. Copyright 2018 American Chemical
Society.61
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Figure 5.2 Chemoenzymatic strategy for the site-specific incorporation of DBCO-DEN-TCO to
the heavy chain glycans of huA33. This scheme was originally published in Cook, B.E. et al.
Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations, Bioconjugate
Chemistry, 2018, 29, (8), pp 2734–2740. Copyright 2018 American Chemical Society.61

5.4

In Vivo biodistribution Studies
Initial biodistribution experiments were conducted using the

ss

huA33-DEN-TCO

immunoconjugate with either a 72 or 120-hour localization time. Traditionally a 24 hour
pretargeting interval is used with huA33-TCO, however previous studies show that the increased
number of TCOs per conjugate can be leveraged to allow more time for the the antibody to
localize.61 This was compared to a non-site-specific TCO-conjugated huA33 with ~4 TCO
moieties per antibody. As can be seen in Figure 5.3, tumor uptake is nearly doubled at 120 h post76

injection of radioligand when comparing mice administered sshuA33-DEN-TCO (22.98 ± 2.2
%ID/g) to a non-specific huA33-TCO (12.66 ± 2.6 %ID/g) with a 72 h pretargeting interval. There
is a similar trend when using a 120 h preinjection interval (17.84 ± 1.8 %ID/g for sshuA33-DENTCO and 10.56 ± 4.5 %ID/g for huA33-TCO) though the overall tumor uptake was lower (Figure
5.4). Interestingly, blood uptake is higher in the cohorts administered the dendritic antibody. This
is in line with previous findings that attribute the higher retention to a longer blood half-life of the
immunoconjugate.61 The longer half-life was determined to arise due to the site-specific cleavage
of the heavy chain glycans.

Figure 5.3 A) In vivo biodistribution results of athymic nude mice bearing subcutaneous SW1222
xenografts (n = 4 per cohort). Mice were administered sshuA33-DEN-TCO (blue bars; 100 µg,
0.67 nmol) or huA33-TCO(grayscale; 100 µg, 0.67 nmol) 72 hours prior to the injection of
[177Lu]Lu-DOTA-PEG7-Tz (300 µCi, 11.1 MBq; 0.7 nmol). B) Calculation of mouse dosimetry
based on biodistribution results.

77

Figure 5.4 A) In vivo biodistribution results of athymic nude mice bearing subcutaneous SW1222
xenografts (n = 4 per cohort). Mice were administered sshuA33-DEN-TCO (pink bars; 100 µg,
0.67 nmol) or huA33-TCO (grayscale; 100 µg, 0.67 nmol) 120 hours prior to the injection of
[177Lu]Lu-DOTA-PEG7-Tz (300 µCi, 11.1 MBq; 0.7 nmol). B) Calculation of mouse dosimetry
based on biodistribution results.

5.5

Dosimetry
This resulting increase in tumor accumulation directly translates into radiation dose

absorbed by the tumor, which is likewise doubled when using the dendritic antibody construct
(Figure 5.3B and Figure 5.4B). Unfortunately, while an impressive increase in tumor uptake was
observed, the therapeutic index (a ratio of radiation dose to tumor: radiation dose to healthy tissue)
did not increase due to the prolonged circulation time of the dendritic antibody and consequential
increase in absorbed dose to the blood. This would result in no significant decrease to overall
dosimetry when extrapolated to a human model. In an effort to improve this finding, use of a
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masking agent will be introduced to potentially clear background organ accumulation and
retention.

5.6

Masking agent, Tz-DP and sshuA33-DEN-TCO
In an effort to decrease antibody remaining in the blood pool while maintaining the higher

tumor uptake, a masking agent (Tz-DP) was used in conjunction with sshuA33-DEN-TCO. For
initial efforts using the masking agent, the quantity of Tz-DP administered in previously published
pretargeted PET experiments as well as the timing for injection were maintained.59 To that end,
100 µg (0.67 nmol) of sshuA33-DEN-TCO was injected intravenously into SW1222 xenograft
bearing mice 72 hours prior to i.v. injection of 55 nmol of Tz-DP. This was followed 30 minutes
later by i.v. injection of [177Lu]Lu-DOTA-Tz (11.1 MBq, 0.7 nmol Tz).
As can be seen in Figure 5.5A, blood activity is significantly decreased as a result of the
masking agent. Unfortunately, tumor uptake is also decreased. It is interesting to note here that in
masking agent-free mice, the amount of activity in the tumor rises substantially over the time
course of the study from 4.92 ± 1.0 %ID/g at 4 h to 22.98 ± 2.2 %ID/g at 120 h. Mice administered
masking agent, however, do not see as drastic of an increase with tumor uptake rising from 2.39 ±
0.5 %ID/g at 4 h to 7.51 ± 1.9 %ID/g at 120 h. This agrees with our results from chapter 4, and
suggests that a significant amount of tumor uptake in pretargeting approaches is driven by
circulating antibody clicking in the blood and then binding to the tumor over time. The masking
agent serves to eliminate this route of binding and so tumor uptake is substantially lower.
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Figure 5.5 Biodistribution of in vivo pretargeting with sshuA33-DEN-TCO and[177Lu]Lu-DOTAPEG7-Tz in athymic nude mice bearing subcutaneous SW1222 human colorectal cancer tumors
using a pretargeting interval of 72 hours (n = 4 per time point). Mice received no masking agent
(blue) or a 30 min preinjection of 55 nmol of Tz-DP (orange).

Surprisingly, an appreciable and increasing uptake in the lungs over time can be observed
in mice receiving a combination Tz-DP and sshuA33-DEN-TCO. This suggests first that TCO
groups on circulating sshuA33-DEN-TCO antibody are being incompletely masked, as they are
still able to click to the radioligand. Second, when radioligand is introduced, Tz-DP, sshuA33DEN-TCO, and [177Lu]Lu-DOTA-Tz may aggregate into a structure large enough to get trapped
in the lungs.63, 64 This phenomenon was not observed in the analogous biodistribution study
combining Tz-DP with a non-specific huA33-TCO (Figure 4.10), and it is well known that
dextrans and antibodies alone are mostly cleared through the hepatobiliary route. 65, 66
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5.7

Conclusion
We have successfully demonstrated that increasing the number of TCO moieties per

antibody results in higher tumor accumulation with a therapeutic radioligand. This has translated
directly to increased absorbed radiation dose at the tumor. However, therapeutic index was not
improved when using the dendritic antibody - a result of increased radiation dose to the blood.
Combination of sshuA33-DEN-TCO with a masking asking effectively decreased this blood pool
retention and our findings were in line with the purpose of a masking agent: clear activity from
accumulating in background organs. However, absolute tumor radiation absorbed dose was also
decreased when compared to non-masking agent pretargeting. This ultimately leads to the
conclusion that the dose and structure of masking agent administered needs to be investigated
further for pretargeted therapeutic applications. It is our firm belief that finding ways of
maintaining higher tumor accumulation, as achieved with the

ss

huA33-DEN-TCO, while

combining with use of a masking agent will enable pretargeted radioimmunotherapy’s translation
to clinical studies.
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Chapter 6:

Pretargeted Alpha Therapy of Colorectal Carcinoma Utilizing the In Vivo
Generator Actinium-225

Disclaimer: Adapted with permission from The Royal Society of Chemistry. Poty, S.; Membreno,
R.; Glaser, J. M.; Ragupathi, A.; Scholz, W. W.; Zeglis, B. M.; Lewis, J. S.The inverse electrondemand Diels–Alder reaction as a new methodology for the synthesis of

225

Ac-labelled

radioimmunoconjugates. Chem. Commun., 2018, 54, 2599-2602. Copyright 2018 The Royal
Society of Chemistry.

6.1

Introduction
Actinium-225 (225Ac; t1/2 = 10.0 d; 5.8 MeV α) is a radionuclide commonly referred

to as an in vivo “nanogenerator” for its characteristic decay by 4 alpha and 2 beta particles
(Figure 6.1).67 Each radioactive atom that is deposited at the tumor therefore produces
multiple radioactive emissions, increasing the potential for cytotoxic damage and therefore
the overall potency of the treatment. Furthermore, the high energy and short range of alpha
particles leads to more specific tumor cell damage by reducing crossfire to healthy cells.
This distinctive feature makes

225

Ac a promising therapeutic in the field of targeted alpha

therapy. For example, in 2016 a multicenter Phase I study was performed to investigate the
therapy of acute myeloid leukemia using an 225Ac labeled radioimmunoconjugate. Patients
displayed disease remission after treatment with a

225

Ac directly labeled humanized anti-

CD33 antibody in combination with low-dose cytarabine, a common chemotherapy drug.
The Phase II and III studies are underway investigating higher dose administered and
response rate.68,10
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Figure 6.1 The 225Ac decay chain to stable 209Bi. Photons with a branching ratio >3% relative to
225

Ac decay are shown. Figure Courtesy of Dr. Jasmine L. Hatcher.

More recently,

225

Ac has been conjugated to a PSMA targeting ligand for the

treatment of metastatic castration-resistant prostate cancer.69 After binding at the tumor site,
the PSMA ligand is internalized into the cell thereby sequestering the 225Ac nanogenerator
and preventing systemic redistribution of the daughter isotopes.67 Thus, any redistribution
in the case of

225

Ac, is mostly

213

Bi by passive diffusion out of the cell and localization in

the kidneys.70 As a result, the dose limiting organs for internalizing vectors of 225Ac are the
kidneys and salivary glands.70 Non-internalizing vectors primarily demonstrate
hematological toxicity due to the irradiation of red marrow during circulation. While
sometimes detrimental, such irradiation has proven effective in treatment of diffuse or
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metastatic disease; a key example of how isotopes and modes of decay should be matched
to the disease morphology.68
While there have been significant achievements in the treatment of diffuse tumors
with targeted alpha therapy, there have been no clinical studies targeting solid tumors by
alpha and few using beta particles. This dearth is likely due to the limited preclinical success
resulting from the lack of tumor penetration by antibodies and radioresistance of solid
tumors.71 Additionally, the antibody-vector must be labeled with a long-lived isotope,
i.e:225Ac, to ensure enough activity remains once optimal biodistribution is reached. This
results in higher radiation doses delivered to healthy cells while the radioimmunoconjugate
is en route to its destination. Pretargeting of the antibody vector, followed by quick
clearance of a small molecule radioligand may allow for high tumor uptake while
simultaneously lowering radiation dose to healthy cells. This pretargeted strategy may pave
the way for capitalizing on the high potency of targeted alpha therapy for aggressive
disease, while skirting the hematological toxicity found with non-internalizing vectors.
In this chapter, a proof-of-concept study is presented to support the idea of
pretargeted alpha therapy. To that end, we used a murine colorectal cancer model with a
non-internalizing antibody-antigen pair. The huA33 antibody has already demonstrated
great potential for pretargeted beta-particle therapy of colorectal cancer (Chapter 3), so the
aim of this chapter is to determine if similar therapeutic efficacy can be achieved utilizing
the same system with 225Ac as the therapeutic radionuclide instead of 177Lu.
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6.2

Radiolabeling of [225Ac]Ac-DOTA-PEG7-Tz
225

Ac was received as a nitrate residue and reconstituted using 0.2 M HCl. A solution of

DOTA-PEG7-Tz (15 - 450 µg; 10 - 370 nmol) in NH4OAc buffer (0.25 M, pH 5.5, 200 µL) was
prepared. Next, the desired amount of activity (20 - 900 µCi, 0.7 - 33.0 MBq) was added to the
reaction mixture, and the solution was placed on an agitating thermomixer at 300 rpm for 1 h at
37 °C. After incubation, the progress of the [225Ac]Ac-DOTA-PEG7-Tz radiolabeling was
determined by radio-iTLC and 50 mM EDTA solution as the mobile phase. Free metal will travel
with the EDTA solution while radiolabeled ligand remains at the base of the strip. The iTLC strip
was read twice; once directly after incubation and again at secular equilibrium (24 hours later).
According to the radiochemical purity observed after the first reading, the 225Ac-complexes were
either purified using a C18-light cartridge eluted with 300 µL of ethanol or without further
purification. Radio-iTLC was then used again to determine the final radiochemical purity of the
construct, radiochemical purity was >98 %. The final molar activity of [225Ac]Ac-DOTA-PEG7Tz ranged from 15.3 to 72.8 MBq/µmol; n = 4.

6.3

Conjugation of [225Ac]Ac-DOTA-PEG7-Tz to huA33-TCO
The [225Ac]Ac-DOTA-PEG7-Tz radiolabeling mixture was mixed with a solution of

huA33-TCO in 20 mM sodium acetate and 150 mM sodium chloride (pH 6.7). The reaction was
left at room temperature for 5 min. and the progress of the conjugation was then determined by
radio-iTLC. The silica strips were developed using a 50/50 mixture of ethanol/water to ensure a
good separation of radioligand, [225Ac]Ac-DOTA-PEG7-Tz, and the radioimmunoconjugate
[225Ac]Ac-DOTA-Tz-TCO-huA33. Using a 50/50 mixture of water and ethanol effectively
separates the two, with the radioligand traveling with the mobile phase and the
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radioimmunoconjugate remaining at the base. The reaction conjugation mixture was purified by
size-exclusion chromotagraphy (PD-10) using a 1% BSA, 0.9 % saline solution as the eluent.
Radiochemical purity was > 98 % as determined by radio-iTLC.

6.4

In Vivo Pretargeted Biodistribution
Initial biodistributions were conducted in athymic nude mice bearing subcutaneous

SW1222 xenografts. Mice were randomized into groups and warmed gently using a heat lamp to
cause swelling of the lateral tail vein prior to being administered huA33-TCO (100 µg, 0.6 nmol
in 150 µL of 0.9% saline) 24 hours prior to radioligand injection. A 24-hour antibody accumulation
interval was maintained from our previous time-optimization studies (Chapter 3). Radiolabeling
mixtures for administration to animals were injected at least 4 h after the purification of the
radiotracers to allow actinium to reach a state close to secular equilibrium and have a good reading
of the activity injected. Activity measurements were obtained using a Capintec CRC-15R Dose
Calibrator (Capintec, Ramsey, NJ) and multiplying the displayed activity value by 5 for a more
accurate measure of the alpha emitting isotope. [225Ac]Ac-Tz-PEG7-DOTA (0.5 µCi; 18.5 kBq,
0.04 nmol) was injected and organs were harvested at designated time points post administration
of radioligand (n = 5 per time point). The percentage of injected dose (% ID) was determined by
counting standards prepared from the formulated radiotracer concurrently with the harvested
samples. The same standards were used to convert the injected weight of the formulated solution
into counts. Organs were counted on a Wizard 2 gamma counter 24 hours after collection (secular
equilibrium) and counts from each sample were decay and background corrected then converted
to % ID/g.
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6.5

“Preclicked” Biodistributions
Athymic nude mice bearing subcutaneous SW1222 xenografts were randomized into

groups and warmed gently using a heat lamp to cause swelling of the lateral tail vein. Doses of
“preclicked” [225Ac]Ac-DOTA-Tz-TCO-huA33 were drawn and injected at least 4 h after the
purification of the radiotracers to allow actinium to reach a state close to secular equilibrium and
have a good reading of the activity injected. Activity measurements were obtained using a Capintec
CRC-15R Dose Calibrator (Capintec, Ramsey, NJ) and multiplying the displayed activity value
by 5 for a more accurate measure of the alpha emitting isotope. [225Ac]Ac-DOTA-Tz/TCO-huA33
(0.5 µCi, 18.5 kBq; 13.2 µg, 0.09 nmol) was injected via tail-vein and organs were harvested at
designated time-points post-administration of radioligand. The percentage of injected dose (% ID)
was determined by counting standards prepared from the formulated radiotracer concurrently with
the harvested samples. The same standards were used to convert the injected weight of the
formulated solution into counts. Organs were counted on a Wizard 2 gamma counter 24 hours after
collection (secular equilibrium) and counts from each sample were decay and background
corrected then converted to % ID/g.

87

A.

25

24 h
Preinjection
4h
24 h
72 h
168 h

%ID/g

20
15

48 h
Preinjection
4h
24 h
72 h
168 h

10
5

e
on
B

Lu
ng
s

or

Li
ve
r
Sp
le
en
St
om
ac
h
Sm
.I
nt
.
Lg
.I
nt
.
K
id
ne
y
M
us
cl
e

B.

Tu
m

B

lo

od

0

200

4h

150

24 h

72 h

168 h

10d

%ID/g

100
50
30
20
10

Li
ve
r
Sp
le
en
St
om
ac
Sm h
.I
nt
.
Lg
.I
nt
.
K
id
ne
y
M
us
cl
e
B
on
e

Lu
ng
s

or

Tu
m

B

lo

od

0

Figure 6.2 In vivo biodistribution in SW1222 tumor bearing athymic nude mice (n = 5 per time
point) of A) the pretargeting system huA33-TCO + [225Ac]Ac-DOTA-PEG7-Tz (100 µg, 0.7nmol
huA33-TCO + 18.5 kBq, 0.5 µg, 0.4 nmol Tz) with a 24 (purple) or 48 (green) hour preinjection
interval and B) preclicked [225Ac]Ac-DOTA-Tz-TCO-huA33 (0.5 µCi, 18.5 kBq; 13.2 µg 0.09
nmol).

“Preclicking” of the radioligand [225Ac]Ac-DOTA-PEG7-Tz with the immunoconjugate
huA33-TCO served as our directly radiolabeled immunoconjugate used in conventional
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radioimmunotherapy. This construct was used as a control to compare with the pretargeting
approach being tested. Preinjection intervals of 24 and 48 hours were used for the pretargeting
studies. In agreement with our previous studies using [177Lu]Lu-DOTA-PEG7-Tz, tumor uptake
was highest utilizing the 24 hour interval time with similar profiles for both preinjection intervals
in all other organs. Interestingly, when tumor uptake is compared to the directly labeled
radioimmunoconjugate, it is only one-tenth of the uptake achieved (Figure 6.2). This may be
because in conventional RIT, the antibody remains in the blood with tumor localization occurring
throughout the duration of its circulation. In pretargeting, the extent of this prolonged tumor
accumulation is minimized mostly because the radioligand is quickly excreted from the body and
does not have as much time to accumulate at the tumor. This faster clearance can be seen in activity
reductions to every background tissue sampled, including the highly radiosensitive kidneys and
bone.
Despite reductions in overall background organ uptake and radioligand clearance, it is
important to consider the therapeutic index, or dose delivered to tumor relative to limiting dose
delivered to background tissue. If less activity is delivered to the tumor, more will need to be
administered initially, thereby increasing overall background dose. This can be illustrated by
tumor-to-tissue ratios which allow us to gauge the potential dosimetric benefits of pretargeting in
our model system. While reductions were seen in background organ uptake, this was not enough
to compensate for the reduction in tumor uptake (Table 6.1). This led to the ratios for the
conventional radioimmunoconjugate far exceeding those for the pretargeting cohorts. In noninternalizing vectors coupled with 225Ac, the kidneys are usually the dose limiting organ resulting
from redistribution of daughter nuclide 213Bi. Surprisingly, tumor-to-kidney ratio was highest for
the directly labeled immunoconjugate with an 8-fold reduction when compared to the 24 h
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pretargeted cohort. This suggests a need to maximize tumor uptake in a pretargeting strategy for it
to effectively provide benefits over traditional RIT.
Preclicked
[225

Ac]Ac-

DOTA-PEG7-TzTCO-huA33

Pretargeted

Pretargeted

huA33-TCO +

huA33-TCO +

[225Ac]Ac-

[225Ac]Ac-

DOTA-PEG7-Tz

DOTA-PEG7-Tz

(24 h interval)

(48 h interval)

Tumor:Blood

46.9 ± 37

34.3 ± 16

26.5 ± 9

Tumor:Heart

257.9 ± 164

77.7 ± 16

48.5 ± 6

Tumor:Lungs

179.1 ± 121

38.2 ± 8

26.5 ± 5

Tumor:Liver

37.9 ± 18

17.6 ± 4

3.3 ± 1

Tumor:Spleen

25.2 ± 20

27.1 ± 5

14.3 ± 3

530.9 ± 271

232.8 ± 100

103.6 ± 26

451.3 ± 271

221.5 ± 43

131.5 ± 40

430.4 ± 295

303.5 ± 63

161.9 ± 36

Tumor:Kidney

187.4 ± 111

22.7 ± 4

14.7 ± 1

Tumor:Muscle

715.7 ± 432

317.5 ± 238

304.9 ± 255

69.9 ± 48

60.4 ± 26

16.8 ± 5

Tumor:Stomach
Tumor:Small
Intestine
Tumor:Large
Intestine

Tumor:Bone

Table 6.1 Tumor-to-tissue ratios extracted from the 168 h time point of the biodistribution of
preclicked [225Ac]Ac-DOTA-Tz-TCO-huA33 (18.5 kBq, 13.2 µg 0.09 nmol ) and pretargeted
huA33-TCO + [225Ac]Ac-DOTA-PEG7-Tz (100µg, 0.7nmol A33-TCO + 18.5 kBq, 0.5 µg, 0.4nmol)
with a 24 and 48 h preinjection interval (n = 5) .
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6.6

Conclusion
We have successfully labeled our Tz-PEG7-DOTA ligand with the alpha emitting nuclide

225

Ac with high radiochemical purity and acceptable yield. We have shown that in vivo pretargeting

affords high tumor uptake and low background organ uptake. When compared to a “preclicked”
radioimmunoconjugate, tumor-to-tissue ratios are far more marginal. For pretargeted
radioimmunotherapy to warrant clinical translation, the tumor uptake must increase such that
tumor-to-tissue

ratios

are

able

to

meet

or

even

surpass

that

of

conventional

radioimmunoconjugates. To that end, the dendrimer scaffold presented in chapter 5 stands primed
to be the next generation of antibody conjugate for the application of pretargeted
radioimmunotherapy with alpha particles.

Chapter 7:
7.1

Fluorescence Imaging of MC1R in Malignant Melanoma

Introduction
The ability to identify and exploit biomarkers for early cancer diagnosis is critical for early

treatment and improved patient survival. Early diagnosis of malignant melanoma is critical, as its
incidence is rising fast and projected to increase by 62% in the next 20 years.72, 73 Currently, the
most effective method of protection against developing melanoma is minimizing exposure to
ultraviolet radiation from sunlight.74 The primary form of treatment for the disease is surgical
excision with concomitant diagnosis confirmed by biopsy75. This form of diagnosis, while
accurate, is invasive and cannot distinguish between primary and metastatic lesions. As a result,
new non-invasive whole-body imaging techniques must be developed to accurately measure the
extent of disease progression.
New tools have been developed for improved assessment beyond visual inspection.
Epiluminescence microscopy, or dermoscopy, allows for 10x magnification of suspicious lesions
using a dermatoscope, an optical device that allows for visualization of the surface and sub-surface
morphology of lesions allowing for more accurate diagnosis.74,
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Despite the accuracy in

visualizing morphology, the use of dermoscopy by primary care physicians is low and only about 60%
of dermatologists use it for the early diagnosis of skin cancer. The main reason for this is the “excessive
training” required for differentiating skin lesions.77,

78 79

While automated instrumentation with

computer aided analysis may prove to be a contender for early, non-invasive detection of skin cancer,
development of imaging agents would allow for physicians to non-invasively determine histological
characteristics of possible malignancies.
Targeted imaging agents require a biomarker to be overexpressed on the surface of the
diseased tissue with minimal expression on healthy tissue to afford good signal contrast.
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Melanocortin 1 Receptor (MC1R) is a promising candidate for the targeted imaging of malignant
melanoma as it is overexpressed in 83 percent of human malignant melanoma cell lines and at low
levels in normal tissue, most abundant in melanocytes with approximately 700 receptor
sites/cell.80, 81 80, 82 MC1R is a member of a class of five melanocortin G-protein receptors which
are responsible for various physiological functions such as pigmentation, inflammation, sexual
function, and energy homeostatis.81 When bound by an agonist, the ligand–receptor complex
internalizes into the cell.83 While this presents an exciting opportunity for the intracellular delivery
of pharmaceuticals, it may also prove effective for the localization of imaging agents.
Four endogenous agonists for the MCR proteins are commonly known: the melanocortin
peptides α-, β-, and γ-melanocyte-stimulating hormone (α-, β-, γ-MSH) and adrenocorticotropic
hormone (ACTH). The five MCRs have differing affinities for the melanocortin peptides with
MC1R having highest affinity for the peptide sequence α-MSH.81, 84 Due to this affinity, many
groups have developed α-MSH derivatives for applications in SPECT and PET imaging of
malignant melanoma.85-90 Recent studies using a
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Ga labeled NOTA variant of the peptide

Norleucine-c[Aspartate-Histidine-D-Phenylalanine-Arginine-Tryptophan-Lysine],

CycMSHhex,

for SPECT imaging showed high tumoral uptake (26.96 ± 3.82 %ID/g) in B16F1 melanoma
subcutaneous xenografts but also high retention in the kidneys (16.42 ± 2.99 %ID/g).90 While most
reports show significant tumor uptake, they also show persistent kidney uptake as a result of the
radiolabeled peptide’s clearance route. This presents a challenge for image contrast but also for
radiation dose delivered to the kidneys.
One alternative strategy to avoid the non-specific radiation dose it to label the peptide with
a fluorophore for optical imaging. Optical imaging relies on the use of an external light source to
stimulate a fluorescent emission from an injectable dye. It has been shown effective particularly
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in surgical settings, where poorly delineated tumors require surgeons to remove large portions of
healthy tissue to avoid missing small infiltrates of malignant tissue.91 The use of a fluorescent dye
provides clear optical visualization and distinction of diseased tissue without the need for extensive
histopathological analysis. In the following section, we describe the conjugation of CycMSHhex to
a near-infrared fluorophore and investigate dosing and biodistribution profiles with the aim of in
vivo fluorescence imaging of malignant melanoma.

7.2

Materials and Instrumentation
The

peptide

Norleucine-c[Aspartate-Histidine-D-Phenylalanine-Arginine-Tryptophan-

Lysine], CycMSHhex, was purchased in > 95% purity from neoScientific (Woburn, MA). The
fluorophores AlexaFluro680 and Dylight680-PEG4 were purchased from SigmaAldrich. All
HPLC purifications (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in CH3CN) were
performed on a Shimadzu UFLC HPLC system equipped with a DGU-20A degasser, a SPD-M20A
UV detector, two LC-20AP pump systems, a CBM-20A communication BUS module, and a FRC10A fraction collector using a reversed-phase C18 XTerra® Preparative MS OBDTM column (10
µm, 19.2 mm × 250 mm; 10 mL/min) or a reversed-phase C18 semi-Prep Phenomenex® Jupiter
column (5 µm, 10 mm × 250 mm; 2 mL/min). Analytical HPLC runs were performed using a
reversed-phase C18 Phenomenex® Jupiter column (5 µm, 4.6 mm × 250 mm; 1 mL/min). Mass
spectrometry was performed using Waters ZQ quadrupole spectrometer equipped with an ESCI
electrospray, chemical ionization ion source and a Waters 2695 HPLC system (Waters, Milford,
MA).
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Figure 7.1 Structure of CycMSHhex. Cyclization was side chain to side chain between the amine
group of the lysine and the carboxy group on the aspartate. The free amine group on the
Norleucine is the intended site of fluorophore conjugation.

7.3

Synthesis of CycMSHhex-AF680
A sample of CycMSHhex (1 mg; 1.0 µmol) was dissolved in 400 µL DMSO and added to a

solution of AF680-NHS (1 mg, 1.0 µmol, 1.0 M) in DMSO. 1.6 µL DIPEA (9.4 µmol; 9.4 molar
equivalents) was then added to this solution, and the reaction placed on an agitating thermomixer
at 600 rpm for 24 hours at 25 °C. The reaction was then purified via preparative C18 HPLC using
a gradient of 5:95 CH3CN:H2O (both with 0.1% TFA) to 95:5 CH3CN:H2O over 30 min (tR = 18.0
min). Lyophilization of the HPLC eluent yielded the purified product as a 1.4 mg of a deep blue
powder (MW = 1823 g/mol; 76% yield). ESI-MS(+): m/z (%) = 1823.8710 [M+H]+; 912.4379
[M+2H]2+.
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Figure 7.2 Synthetic Route of CycMSHhex-AF680 conjugation. Simple primary amine NHS ester
chemistry allows for straightforward sysnthesis of our desired fluorophore-peptide in 76 % yield

7.4

Synthesis of CycMSHhex-PEG4-DyLight680
In addition to the peptide directly conjugated to a fluorophore, a PEG linker was introduced

to investigate potential hindrance in binding as a result of the fluorophore addition. To that end, a
commercially available NHS ester fluorophore with a PEG4 linker with the same excitation
wavelength as AF680 was purchased from Sigma Aldrich. The structure, and therefore molecular
weight, of DyLight680-PEG4-NHS is held as proprietary information by the manufacturer. As a
result an estimate of the final construct molecular weight was calculated based on ESI-MS results
of the peptide and fluorophore starting materials and the theoretical mass of the Nhydroxysuccinimide leaving group (Figure 7.3).
A sample of CycMSHhex (0.7 mg; 0.7 µmol) was dissolved in 400 µL DMSO and 1.0 µL of
DIPEA (5.7 µmol; 8.1 equivalents) was then added to this solution. A solution of Dylight680PEG4-NHS (0.1 mg, 0.5 µmol) in DMSO was then added to the peptide and the solution was placed
on an agitating thermomixer at 600 rpm for 3 hours at 25 °C. The reaction was then purified via
preparative C18 HPLC using a gradient of 5:95 CH3CN:H2O (both with 0.1% TFA) to 95:5
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CH3CN:H2O over 30 min (tR = 18.6 min). Lyophilization of the HPLC eluent yielded the purified
product as a 0.4 mg of a deep blue powder (MW = 2529 g/mol; 0.71 µmol; 21% yield). ESI-MS(+):
m/z (%) = 1265.9 [M+2H]2+; 844.4 [M+3H]3+.
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Figure 7.3 Synthetic Route of CycMSHhex-DyLight680 conjugation. As the molecular weight of
DyLight680-PEG4-NHS is proprietary information, an estimate of the final construct molecular
weight was calculated based on ESI-MS results of the peptide and fluorophore starting materials
and the theoretical mass of the N-hydroxysuccinimide leaving group.

7.5

Cell Culture
B16F1 mouse melanoma cells were grown in Dulbecco’s Modified Eagle’s Medium

(DMEM) containing 10% fetal bovine serum, 100 units/mL penicillin and 100 µg/mL
streptomycin in 5% CO2 at 37°C. The B16F1 cells were obtained from American Type Culture
Collection (ATCC). All experiments were performed with cells of passage number less than 15.

7.6

Flow Cytometry
Flow cytometry analysis was performed to determine if these conjugates bound to the MC1

receptor expressed on B16F1 cells. Samples were prepared in 50 µL of FACS buffer (0.05% FBS
and 2 mM EDTA in PBS) such that there were 4 million cells per sample. Fluorescently labeled
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peptide was added to each sample in decreasing concentrations ranging from 380 µM to 1.5 µM
(950 mg/mL to 3.7 mg/mL) and were incubated on ice for 45 minutes. Cells were then washed
twice with PBS to remove free peptide before being re-suspending in FACS buffer for analysis.
B16F1 cells with no addition of labeled peptide were used as a negative control of binding.
A clear concentration dependent shift in fluorescence is observed with both peptides at
concentrations of about 30 µM and 50 µM for the AF680-peptide and DyLight680 peptide,
respectively. While there is a shift occurring, there is also a broadening of the signal which implies
heterogeneous binding of the peptide. This could be attributed to heterogeneous expression of
MC1R on our B16F1 cells, and is supported by the presence of two populations of cells as seen by
the flow cytometry (Figure 7.5 and Figure 7.6). From the control of B16F1 only cells, we can see
that the cells with no fluorescence signals exist in the bottom left quadrant (Figure 7.4). The signal
in this quadrant is always present, even in the flow cytometry samples that have been incubated
with fluorophore-peptide. A positive antibody control known to bind MC1R could be an additional
experiment to investigate the binding capacity of the receptor-peptide interaction.
Alternatively, in the described peptide design, three potential primary amines are available
for conjugation to the NHS-fluorophore (side chain of arginine, pKa = 12.48; the amide group of
the lysine; or the N-terminus of norleucine, pKa = 9.76). The binding motif of the peptide for the
receptor is the sequence (His)-(D-Phe)-(Arg)-(Trp), which means if conjugation occurred on the
arginine, there may be a disruption to the binding affinity to MC1R. While we do not have
definitive evidence of exact site of binding, as all three conformers have the same molecular
weight, we do not believe conjugation occurs through arginine, as its pKa is above the pH used
during conjugation methods (8.8 - 9) or the lysine as amides are not readily reactive.
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Figure 7.4 MC1R expressing B16F1 melanoma cells used as a negative control for flow cytometry
experiments.
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Figure 7.5 Flow Cytometry results of MC1R expressing B16F1 melanoma cells incubated with
CycMSHhex-Dylight680. A concentration dependent nature of binding is observed with no
fluorescence shift in the cell only control.
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Figure 7.6 Flow Cytometry results of MC1R expressing B16F1 melanoma cells incubated with
CycMSHhex-AF680. A concentration dependent nature of binding is observed with no
fluorescence shift in the cell only control.
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7.7

Subcutaneous Xenograft Implantation
Female athymic nude mice aged 6-8 weeks were injected subcutaneously in the right flank

with 1 × 106 B16F1 cells suspended in Hank’s Balanced Salt Solution (HBSS). Black C57BL/6
mice aged 6-8 weeks were put under anesthesia (2% isofluorane) and their right flank shaved to
view the skin. 1 × 106 B16F1 cells suspended in HBSS were then implanted subcutaneously onto
the right flank. Tumors were grown for 10-12 days before imaging experiments.

7.8

In Vivo Fluorescence Imaging
Mice bearing subcutaneous B16F1 xenografts were administered a low (0.2 µg), medium

(2.1 µg), or high (6.8 µg) dose of Dylight680-CycMSHhex or a low (0.15 µg) or high (4.9 µg) dose
of AF680-CycMSHhex by tail vein injection (n = 1). Fluorescence imaging was performed 0.5, 2,
4, and 8 hours following injection of peptide (Figure 7.7). Organs were harvested following the
final imaging time point from the mice receiving the highest dose of each peptide, washed and
dried in open air for 5 minutes and imaged ex vivo (Figure 7.8).

Table 7.1 Administered doses of fluorescently labeled peptides (n = 1).
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Figure 7.7 Fluorescence imaging of mice following injection of either Dylight680-CycMSHhex or
AF680-CycMSHhex

Figure 7.8 Ex vivo fluorescence imaging of select organs 8 hours after administration of labeled
peptides. First two columns represent the athymic mice that received the highest dose of AF680CycMSH or Dylight-CycMSH, respectively. Final two columns are the C57BL/6 mice that received
the highest dose of AF680-CycMSH or the medium dose of Dylight680-CycMSH (n = 1).
103

The pilot fluorescence imaging study consisted of 5 mice bearing subcutaneous B16F1
xenografts (Figure 7.7). The initial study was to determine an optimal dose for high tumor
accumulation and fast clearance. To that end, previous published work used 3 nmol/kg as an
effective dose for tumor uptake, so this was chosen as the low dose.90 We then chose 2 doses an
order of magnitude greater to view a range of dosing. Dylight680-CycMSH was administered to 3
out of 5 mice because the addition of the PEG linker may give it a longer opportunity for circulation
and tumor accumulation.92, 93 AF680-CycMSH was administered to the remaining two mice in
either a high or low dose to view the extremes of the dosage window.
As expected, kidney uptake was clearly seen in mice administered the PEGylated
Dylight680, though all compounds tested also exhibited hepatobiliary clearance through the
stomach and intestines. In all cohorts, no uptake was observed in the tumor. This may have been
due to insufficient peptide administered or heterogeneous expression of the MC1 receptor on the
B16F1 cell line, or disruption of binding affinity due to fluorophore incorporation. The flow
cytometry results clearly show two populations- those cells with bound fluorophore and those
without. A positive control antibody or peptide ligand would be useful in determining the
significance of this phenomenon. One could speculate that the incomplete binding of all the cells
was a concentration issue, with not enough peptide present in incubation. However, it required
almost 400 µM of Dylight680-CycMSH for complete shift in the flow cytometry. This would
translate to about 1 g of fluorescent-peptide per mouse. When considered for eventual translation,
this is not a feasible dose for administration and so further work was not pursued.
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7.9

Conclusion
Though no tracer was successfully developed in this brief project, some important lessons

were learned along the way. If we were to move forward to optimize this strategy, it would first
be prudent to fully characterize cell expression of the receptor and quantify binding affinities of
both modified and unmodified ligand. This would have allowed us to eliminate receptor variability
as a possible cause of peak broadening on FACS and low tumor uptake. We did observe some
interesting phenomena - such as the changes in biodistribution that occurred with the addition of a
PEG linker and fluorophore - that help solidify previously published data.
While much of this seems to be making lemons from lemonade, it is interesting to note that
this was the first solo project I undertook in graduate school (despite it serving as the final chapter
of my thesis). While some mistakes were made along the way, I believe that the lessons learned
from them can be seen throughout the previous sections and contributed to the ultimate success of
my time in graduate school.
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